Cefadroxil

Authoritative Clinical Reference

DRUG NAME: Cefadroxil

INN: Cefadroxil
Salt form used clinically: Cefadroxil monohydrate. All oral formulations in India use the monohydrate salt. Doses throughout this monograph are expressed as cefadroxil base equivalent (i.e., the labelled strengths of 250 mg, 500 mg, and 1 g refer to the base activity, not the monohydrate weight). Prescribers need not specify the salt — all marketed products are the monohydrate.

ℹ️ Relationship to cephalexin: Cefadroxil is the para-hydroxy derivative of cephalexin — structurally, the only difference is a hydroxyl group on the phenyl ring of the D-phenylglycine side chain. This minor structural modification confers a clinically important pharmacokinetic advantage: a longer half-life (~1.2–1.8 hours vs ~0.6–1.2 hours for cephalexin), enabling twice-daily (BD) dosing rather than three-to-four-times-daily dosing. The antimicrobial spectrum, potency (MICs), and safety profile are essentially identical to cephalexin.

💡 The core clinical question for cefadroxil: In virtually every clinical scenario where cefadroxil is considered, cephalexin is the alternative (and vice versa). The choice between them is almost never about spectrum or efficacy — it is about dosing convenience and adherence. Cefadroxil’s BD dosing is its primary clinical advantage; cephalexin’s wider availability, lower cost (NPPA-controlled), and more extensive evidence base (including for osteomyelitis step-down) are its advantages. This monograph will address this comparison throughout.

Therapeutic Class:

Antibiotic (Antibacterial)

Subclass:

First-generation cephalosporin (oral)

ℹ️ Same subclass as cephalexin, cefazolin (parenteral), cefadroxil, and cephradine. First-generation cephalosporins are characterised by excellent Gram-positive activity (MSSA, streptococci) and limited but useful Gram-negative activity (community-acquired, non-ESBL E. coli, K. pneumoniae, P. mirabilis).

Schedule (India):

Schedule H

All formulations of cefadroxil (capsules, tablets, dry syrup/oral suspension, paediatric drops) are classified under Schedule H. A valid prescription from a registered medical practitioner is required for dispensing.

No formulation of cefadroxil has OTC (non-scheduled) status in India.

Route(s)

Oral (capsules, tablets, dry syrup/oral suspension, paediatric drops)

ℹ️ Cefadroxil is an oral-only drug. There is no parenteral (IV/IM) formulation of cefadroxil. The parenteral equivalent within the first-generation cephalosporin class is cefazolin (IV/IM). When transitioning from IV to oral therapy, cefazolin → cefadroxil is a pharmacologically rational IV-to-oral switch (both first-generation cephalosporins; same spectrum), analogous to the more commonly practised cefazolin → cephalexin switch.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable.

Cefadroxil is a small-molecule, semi-synthetic antibiotic (a first-generation cephalosporin derived from 7-aminocephalosporanic acid, 7-ACA). It is manufactured as a conventional generic pharmaceutical product. Multiple generic manufacturers produce cefadroxil in India.

Formulations Available in India

Single-ingredient formulations:

Dosage Form	Strengths Available	Notes
Capsules (cefadroxil monohydrate)	500 mg	Most commonly prescribed form for adults and older children who can swallow capsules. Some manufacturers also produce 250 mg capsules — verify local availability.
Tablets (film-coated)	500 mg, 1 g (1000 mg — select manufacturers)	1 g tablet is useful for single-tablet high-dose BD therapy (e.g., pharyngitis, serious SSTI). Not all manufacturers produce the 1 g strength — availability may be limited outside major metros.
Dispersible tablets	250 mg, 500 mg (select manufacturers)	Can be dispersed in water for children or patients with swallowing difficulty. Limited availability.
Dry syrup / Oral suspension (powder for reconstitution)	125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL	Widely available from multiple Indian manufacturers. Primary formulation for paediatric use. The 500 mg/5 mL concentration is available from select manufacturers and reduces the volume of each dose for older/heavier children.
Paediatric drops	100 mg/mL (select manufacturers)	For infants where small accurate volumes are needed. Limited availability.

ℹ️ Comparison with cephalexin formulation range: Cefadroxil’s formulation range in India is slightly narrower than cephalexin’s — cephalexin has a broader base of manufacturers and more universally stocked formulations. However, cefadroxil capsules (500 mg) and dry syrup (125 mg/5 mL, 250 mg/5 mL) are widely available from major manufacturers.

Fixed-Dose Combinations (FDCs) available in India:

ℹ️ Cefadroxil has very few commonly used FDCs:

FDC Partner	Strengths Available	Route	Notes
Cefadroxil + Probenecid	Data limited — available from very few manufacturers	Oral	Same rationale as cephalexin + probenecid FDC: probenecid blocks renal tubular secretion → increased cefadroxil levels. Rarely prescribed in current Indian practice.
Cefadroxil + Clavulanic acid	500 mg + 125 mg (select manufacturers)	Oral	⚠️ This FDC is NOT widely established in Indian infectious disease practice. The addition of clavulanic acid to a first-generation cephalosporin is pharmacologically questionable — cefadroxil’s limitations are primarily its narrow Gram-negative spectrum and lack of anaerobic coverage, which clavulanic acid partially addresses. However, amoxicillin-clavulanate is the far more established and evidence-supported BL/BLI combination for this purpose. This cefadroxil-clavulanate FDC is available from limited manufacturers but has no specific endorsement in API Textbook, ICMR guidelines, or AIIMS protocols. Prescribers should use amoxicillin-clavulanate rather than this FDC when a BL/BLI combination is needed.

⛔ Banned FDCs containing cefadroxil:
No FDC containing cefadroxil as a component has been specifically banned by CDSCO as of the latest gazette notifications reviewed (2024). Prescribers should verify the current CDSCO banned drug list periodically.

PHARMACOKINETICS

Parameter	Value
Bioavailability (oral)	~90–95% — excellent oral bioavailability, comparable to cephalexin. Absorption is rapid and nearly complete from the GI tract.
Tmax	~1.5–2 hours (fasting); ~2–2.5 hours (with food). Food delays Tmax slightly but does NOT significantly reduce total absorption (AUC). See Food Effect.
Protein binding	~20% — low protein binding. This means approximately 80% of circulating cefadroxil is free (unbound) and microbiologically active. Similar to cephalexin (~10–15% protein binding). Low protein binding means hypoalbuminaemia does NOT meaningfully alter free drug levels.
Volume of distribution (Vd)	~0.26–0.31 L/kg (~18–22 L in a 70 kg adult). Distribution is similar to cephalexin — primarily into extracellular fluid. Penetrates well into: skin and soft tissues (good — relevant for SSTI), tonsils and adenoid tissue (good — relevant for pharyngitis; tissue levels ~0.5–1.5 mcg/g documented), renal parenchyma and urinary tract (excellent — very high urinary concentrations), middle ear fluid (moderate), bone (moderate). Poor CSF penetration even with inflamed meninges — NOT suitable for CNS infections.
Metabolism	Not significantly metabolised. Cefadroxil is excreted unchanged in the urine — no hepatic metabolism, no CYP450 involvement, no active metabolites. This is a major pharmacological advantage identical to cephalexin: (1) No drug interactions via CYP pathways, (2) No hepatic dose adjustment required, (3) Predictable drug levels. Cefadroxil is NOT a substrate, inhibitor, or inducer of CYP450 enzymes. It is a substrate of PEPT1 (intestinal peptide transporter — mediates active intestinal absorption) and OAT1/OAT3 (renal organic anion transporters — mediates active tubular secretion). It is NOT a significant substrate or inhibitor of P-glycoprotein, OATP1B1/1B3, BCRP, OCT2, or MATE1/2 at therapeutic concentrations.
Half-life (t½)	~1.2–1.8 hours (mean ~1.5 hours) in adults with normal renal function. ℹ️ This is the key PK differentiator from cephalexin (~0.6–1.2 hours, mean ~1 hour). The ~50% longer half-life of cefadroxil, combined with its high oral bioavailability and high urinary concentrations, supports BD (twice-daily) dosing for most indications — compared to TDS (q8h) or QDS (q6h) for cephalexin. Prolonged in renal impairment: up to 8–10 hours at CrCl <10 mL/min; up to 20–25 hours in anuria (slightly longer than cephalexin’s prolongation — reflecting the already longer baseline half-life). Neonates: 3–6 hours (immature renal function).
Excretion	Primarily renal: ~90–95% excreted unchanged in urine via both glomerular filtration and active tubular secretion (via OAT1/OAT3). Achieves very high urinary concentrations (~500–1800 mcg/mL within the first 6–8 hours after a 500 mg dose) — clinically relevant for UTI treatment. Minor faecal excretion (<5%).
Dialysability	Moderately dialysable by haemodialysis — approximately 30–40% removed in a standard 4-hour HD session (low protein binding + moderate Vd → amenable to dialysis clearance). Supplemental dose required post-HD (see Renal Adjustment, Part 4). Peritoneal dialysis removes cefadroxil less efficiently (~10–15%).
Food effect	Not clinically significant. Food slightly delays Tmax (from ~1.5 h to ~2–2.5 h) and marginally reduces Cmax (~10–15% lower peak), but total absorption (AUC) is NOT significantly reduced. ✔ Cefadroxil CAN be taken with or without food. Taking with food may reduce GI side effects (nausea). This is the same practical advantage shared with cephalexin — and a key differentiator from cloxacillin/flucloxacillin (empty-stomach requirement).
Onset of action	Clinical onset: ~1–2 hours after oral dose (time to achieve therapeutic serum and tissue levels). Clinical improvement in infections: typically 48–72 hours.
Duration of action	~10–12 hours per dose — this is the effective dosing interval, supported by the half-life (~1.5 h), high peak levels, and the time-dependent killing PK/PD principle (where the proportion of the dosing interval that free drug levels exceed the MIC — fT>MIC — determines efficacy). For typical susceptible organisms (MIC ≤2–4 mg/L), a 500 mg BD dose maintains fT>MIC for approximately 50–60% of the 12-hour dosing interval — adequate for mild-to-moderate infections in immunocompetent patients. For organisms with higher MICs or in immunocompromised patients, the fT>MIC with BD dosing may be marginal — consider cephalexin q6h or a higher generation cephalosporin.

Non-linear PK:
No clinically significant non-linear pharmacokinetics at therapeutic doses. Absorption via PEPT1 may theoretically saturate at very high single doses (>4 g), but this is not relevant at the standard dose range (500 mg–1 g per dose).

Prodrug status: Cefadroxil is NOT a prodrug. The parent compound is the active antibacterial moiety.

Population PK Notes:

Population	PK Differences
Obesity	Moderate Vd (~0.26–0.31 L/kg) means morbidly obese patients may have somewhat lower peak concentrations at standard doses. For serious infections in morbidly obese patients, use the higher end of the dose range (1 g BD). Specific PK studies in obesity for cefadroxil are lacking — extrapolate from cephalexin data (similar Vd).
Pregnancy	Increased Vd (plasma volume expansion ~40–50%) and increased GFR (~50%) → lower cefadroxil serum levels at standard doses. However, urinary concentrations remain very high (UTI is the most common pregnancy indication), so efficacy for UTI is generally preserved. For non-UTI indications in pregnancy, use the higher end of the dose range.
Critical illness / ICU	Cefadroxil is an oral-only drug and is rarely the drug of choice in the ICU (parenteral agents preferred). If used for oral step-down in a recovering ICU patient, renal function should guide dosing. ARC is not typically a concern for cefadroxil because ICU patients requiring anti-staphylococcal therapy are usually on parenteral agents.
Paediatric	Higher per-kg clearance in children compared to adults. Neonates have prolonged half-life (3–6 hours) due to immature renal function. Weight-based dosing (mg/kg) accounts for the higher per-kg requirements. Oral absorption is generally reliable from ~1 month of age.
Elderly (≥60 years)	Clearance is reduced proportionally to age-related decline in GFR. Half-life may be prolonged to 2–4 hours depending on renal function. Always estimate eGFR/CrCl before prescribing in elderly — a “normal” serum creatinine may mask significant renal impairment in elderly patients with reduced muscle mass. Dose adjustment is based on CrCl/eGFR rather than age per se.

Spectrum of Activity — Quick Reference:

ℹ️ Cefadroxil’s spectrum of activity is essentially identical to cephalexin — both are first-generation cephalosporins with the same mechanism of action (binding to penicillin-binding proteins → inhibiting cell wall synthesis) and the same susceptibility/resistance patterns.

Category	Typical Activity
Gram-positive (aerobic)	✔ Staphylococcus aureus (MSSA only — NOT MRSA): Good. Resistant to staphylococcal penicillinases (beta-lactamases). ✔ Streptococci: Excellent against S. pyogenes (Group A — GAS), Group B Streptococcus (GBS), S. pneumoniae (penicillin-susceptible). ✔ Coagulase-negative staphylococci (methicillin-sensitive only).
Gram-negative (aerobic)	✔ Community-acquired, non-ESBL E. coli: Good. ✔ Klebsiella pneumoniae: Moderate (community-acquired, non-ESBL only). ✔ Proteus mirabilis: Good. ⚠️ Limited to community-acquired, non-resistant strains. Hospital-acquired and ESBL-producing Enterobacterales are resistant.
NO activity against	⛔ MRSA; ⛔ Enterococcus spp. (intrinsically resistant to ALL cephalosporins); ⛔ Pseudomonas aeruginosa; ⛔ Acinetobacter baumannii; ⛔ ESBL-producing Enterobacterales; ⛔ Anaerobes (negligible anaerobic activity); ⛔ Stenotrophomonas maltophilia; ⛔ Atypical pathogens (Mycoplasma, Chlamydia, Legionella); ⛔ Listeria monocytogenes; ⛔ Haemophilus influenzae — variable, borderline activity (second/third-gen cephalosporins preferred)

⚠️ Indian resistance context: Same resistance considerations as cephalexin (see cephalexin monograph for detailed ICMR AMR surveillance data). In summary:

Community E. coli susceptibility to first-generation cephalosporins: ~50–65% (varies regionally)
Community K. pneumoniae susceptibility: ~40–55%
MSSA and GAS remain highly susceptible — resistance is not a concern for Gram-positive indications

Key PK Comparison: Cefadroxil vs Cephalexin

ℹ️ This comparison is the single most clinically relevant context for prescribers considering cefadroxil. It is presented concisely with only the differentiating parameters.

Parameter	Cefadroxil	Cephalexin
Half-life	~1.2–1.8 h (mean ~1.5 h)	~0.6–1.2 h (mean ~1 h)
Recommended dosing frequency	BD (q12h) for most indications	TDS (q8h) or QDS (q6h)
Oral bioavailability	~90–95%	~90–95%
Food effect	Negligible (take with or without food)	Negligible (take with or without food)
Protein binding	~20%	~10–15%
Free drug fraction	~80%	~85–90%
Spectrum	Identical	Identical
NLEM India	✔ On NLEM 2022	✔ On NLEM 2022
NPPA price controlled	✔ Yes	✔ Yes
Cost (per course — typical 7-day SSTI)	Slightly higher (fewer manufacturers, some strengths less competitive)	Slightly lower (more manufacturers, aggressive generic pricing)
Availability in India	Widely available (but fewer brands than cephalexin)	Very widely available (more brands, Jan Aushadhi stocked)
High-dose evidence for osteomyelitis	Limited	More established (1 g q6h — OVIVA trial context, Indian ID practice)
Adherence advantage	✔ BD dosing — fewer daily doses	TDS/QDS — more daily doses

💡 Clinical bottom line: Cefadroxil and cephalexin are therapeutically interchangeable for virtually all clinical indications. The choice between them is driven by:

Adherence priority → choose cefadroxil (BD — 2 doses/day is easier than 3–4)
Cost priority → choose cephalexin (wider generic competition, NPPA-controlled with more ceiling-price products)
High-dose therapy (osteomyelitis step-down) → choose cephalexin (better evidence base at 1 g q6h; cefadroxil 1 g BD is pharmacokinetically marginal for high-MIC organisms due to suboptimal fT>MIC at 12-hour intervals)
Availability priority (rural/remote areas) → check local availability — both are widely available but cephalexin has a slight edge in ubiquity

ADULT INDICATIONS + DOSING

⛔ CRITICAL PRESCRIBING PRINCIPLES — READ BEFORE ALL INDICATIONS:

1. Cefadroxil has the SAME spectrum as cephalexin.
Every spectrum-related limitation and strength described for cephalexin applies identically to cefadroxil. It is a narrow-spectrum, Gram-positive-focused oral antibiotic with moderate activity against community-acquired, non-ESBL Gram-negatives. It has NO activity against MRSA, Enterococcus, Pseudomonas, anaerobes, or ESBL-producing organisms.

2. Cefadroxil’s value proposition is BD dosing.
The clinical rationale for choosing cefadroxil over cephalexin is almost always about dosing convenience and adherence — not about spectrum or potency. Two daily doses (BD) vs three-to-four daily doses (TDS/QDS) is a meaningful practical advantage, especially for:

Outpatient therapy where compliance drops with each additional daily dose
School-going children (BD = morning + evening; no midday school dose)
Working adults (BD = before and after work; no midday workplace dose)
10-day courses (GAS pharyngitis) where the total “pill burden” over the course is substantially lower with BD dosing

3. Once-daily (OD) dosing for GAS pharyngitis — a unique cefadroxil advantage.
Cefadroxil 1 g once daily (or 30 mg/kg/day OD in children) for 10 days has RCT evidence supporting its efficacy for GAS pharyngitis eradication. This OD regimen is NOT available with cephalexin (whose shorter half-life does not support once-daily dosing). This is arguably cefadroxil’s single most distinctive clinical advantage.

4. Culture-guided therapy is always preferred over empiric therapy when feasible.

5. Cefadroxil is an ORAL-ONLY drug. No IV or IM formulation exists. The parenteral equivalent is cefazolin (IV/IM).

6. Same enterococcal and anaerobic gaps as all cephalosporins. See cephalexin monograph for detailed discussion of these fundamental limitations.

GENERAL DOSING FRAMEWORK:

Dosing Parameter	Standard Adult Dosing
Mild-to-moderate infections	500 mg BD (q12h) or 1 g OD (once daily — select indications only)
Moderate-to-severe infections	1 g BD (q12h)
Maximum dose	Max 1 g per dose; Max 2 g per day
Take with or without food	✔ Either acceptable. Taking with food may reduce GI upset.

ℹ️ Dosing frequency rationale: Unlike cephalexin (which uses q6–8h dosing), cefadroxil’s longer half-life (~1.5 h vs ~1 h) and slightly higher Cmax/AUC per dose support a q12h (BD) dosing interval for most indications. For GAS pharyngitis, a q24h (OD) option exists. TDS (q8h) dosing of cefadroxil is occasionally used for severe infections but is not standard — if TDS dosing is needed, cephalexin (which is specifically designed for q6–8h dosing) is the more natural choice.

Primary Indications (Approved / Standard in India)

PRIMARY INDICATION 1: Skin and Soft Tissue Infections (SSTI) — MSSA / Streptococcal

Includes: Cellulitis (non-purulent and purulent — when MSSA suspected/confirmed), impetigo (non-bullous and bullous), wound infections, furunculosis, carbuncle, folliculitis, erysipelas, infected eczema, post-surgical wound infection (MSSA/streptococcal), infected burns (superficial, MSSA/streptococcal), pyoderma, paronychia (acute bacterial), secondary skin infections.

ℹ️ SSTI is the most common indication for cefadroxil in Indian outpatient practice, alongside UTI and pharyngitis. Cefadroxil’s BD dosing provides a meaningful adherence advantage over cephalexin TDS for the typical 5–7-day SSTI course.

Dosing Table — SSTI:

Severity	Dose	Frequency	Maximum	Duration	Clinical Notes
Mild SSTI (localised impetigo, small folliculitis, minor wound infection)	500 mg	BD (q12h)	Max 500 mg per dose; Max 1 g/day	5–7 days	For limited impetigo, topical mupirocin or fusidic acid alone may suffice. Cefadroxil for extensive or topical-failure cases.
Moderate SSTI (cellulitis without systemic signs, larger abscess post-drainage, extensive impetigo, furunculosis)	500 mg–1 g	BD (q12h)	Max 1 g per dose; Max 2 g/day	5–7 days (may extend to 10 days if slow response)	500 mg BD for most moderate SSTI. 1 g BD for deep-seated or slowly responding lesions.
Moderate-to-severe SSTI (spreading cellulitis, large carbuncle, deep wound infection, extensive pyoderma)	1 g	BD (q12h)	Max 1 g per dose; Max 2 g/day	7–10 days	Maximum oral dose. If systemic signs present (fever >38.5°C, tachycardia, hypotension) → switch to IV cefazolin.

Duration of Therapy — SSTI:

Condition	Recommended Duration
Impetigo	5–7 days
Simple cellulitis	5 days (DANCE trial evidence supports short course if responding)
Moderate cellulitis	5–7 days (extend to 10 if slow response)
Abscess (post I&D) — antibiotics adjunctive	5–7 days
Furunculosis / carbuncle	7–10 days
Wound infection (post-surgical)	7–14 days depending on depth

ℹ️ Total pill burden comparison — 7-day SSTI course:

Cefadroxil 500 mg BD × 7 days = 14 capsules total (2 per day)
Cephalexin 500 mg TDS × 7 days = 21 capsules total (3 per day)
Cephalexin 500 mg QDS × 7 days = 28 capsules total (4 per day)
Cloxacillin 500 mg QDS × 7 days = 28 capsules total (4 per day, empty stomach)

The reduction from 21–28 capsules to 14 capsules is practically meaningful for adherence, cost, and convenience.

Mandatory Clinical Notes Checklist — SSTI:

When to prefer cefadroxil over alternatives: Preferred over cephalexin when adherence to TDS/QDS dosing is a concern — school-going children, working adults, elderly on polypharmacy (fewer daily doses → less confusion). Preferred over cloxacillin/flucloxacillin for the same adherence reasons (BD food-independent dosing vs QDS empty-stomach). Preferred when the patient or caregiver specifically requests a simpler regimen. For mild-to-moderate MSSA SSTI, cefadroxil BD and cephalexin TDS are clinically equivalent — the choice is a pragmatic one.
When NOT to use:
- ⛔ Suspected or confirmed MRSA → use TMP-SMX, doxycycline, or clindamycin
- ⛔ Bite wounds (animal or human) → anaerobic component → use amoxicillin-clavulanate
- ⛔ Diabetic foot infection (polymicrobial) → cefadroxil monotherapy insufficient → use amoxicillin-clavulanate or piperacillin-tazobactam
- ⛔ Necrotising fasciitis → IV broad-spectrum + surgical emergency
- ⛔ Perianal / perineal SSTI → anaerobic component likely → add metronidazole or use amoxicillin-clavulanate
- ⛔ Patient with history of anaphylaxis to cephalosporins or penicillins (see Part 4 for cross-reactivity guidance)
NLEM India status: ✔ Cefadroxil is included in NLEM India 2022.
Typical time to clinical response: 48–72 hours. Cellulitis erythema should stop advancing; warmth and tenderness should begin improving. Mark the erythema border with a pen to objectively track progression/regression.
Criteria for considering treatment failure and switching:
- No improvement at 72 hours → (a) reassess diagnosis (DVT, contact dermatitis, stasis dermatitis in leg cellulitis), (b) obtain wound culture, © consider MRSA → switch to TMP-SMX/doxycycline/clindamycin, (d) consider deeper infection (abscess, necrotising) → imaging + surgical consultation
- Worsening despite 48 hours → urgent reassessment, consider IV cefazolin or broader coverage
Mandatory baseline investigations:
- RECOMMENDED: Wound swab culture and sensitivity (before starting — especially if purulent, recurrent, or treatment failure)
- OPTIONAL: CBC, blood glucose (screen for diabetes in recurrent SSTI), renal function (if prolonged course)
Specialist initiation:Not required. Primary care prescribing appropriate for mild-to-moderate SSTI. Complicated or non-responding SSTI → surgical/ID referral.
Relevant Indian guideline source: API Textbook of Medicine (Chapter on SSTI); ICMR Antimicrobial Treatment Guidelines (2022); IDSA SSTI Guidelines (2014 — widely followed in India). ICMR and API Textbook reference first-generation cephalosporins generically for MSSA SSTI (do not specifically differentiate cefadroxil from cephalexin).
Key disease-specific safety warning: ⚠️ In recurrent SSTI (≥3 episodes in 12 months), screen for: (a) diabetes (HbA1c), (b) MRSA nasal carriage (decolonisation protocol), © immunodeficiency, (d) household contacts as reservoirs. Recurrent MSSA SSTI in Indian diabetic patients is extremely common — always optimise glycaemic control alongside antibiotics.
Dose adjustment: Renal impairment (eGFR <30) → see Part 4. Obese patients → 1 g BD. Elderly → adjust for eGFR.

PRIMARY INDICATION 2: Urinary Tract Infections — Acute Uncomplicated Cystitis

ℹ️ Same clinical context as cephalexin — cefadroxil is a second-line agent for uncomplicated cystitis (nitrofurantoin, fosfomycin, and TMP-SMX are preferred first-line when susceptible). Cefadroxil’s BD dosing provides a modest convenience advantage over cephalexin QDS for this indication.

Dosing — Acute Uncomplicated Cystitis:

Dose	Frequency	Maximum	Duration	Clinical Notes
500 mg	BD (q12h)	Max 500 mg per dose; Max 1 g/day	5–7 days	BD dosing is the primary advantage over cephalexin q6–8h for this indication.
1 g	OD (once daily)	Max 1 g per dose; Max 1 g/day	5–7 days	OD dosing for uncomplicated cystitis is supported by the very high urinary concentrations achieved (~1000–1800 mcg/mL). Some experts use this for compliant patients with susceptible organisms. Evidence is moderate — most guidelines recommend BD.

Dosing — Acute Pyelonephritis (Mild, Outpatient — Directed Therapy Only):

Dose	Frequency	Maximum	Duration	Notes
1 g	BD (q12h)	Max 1 g per dose; Max 2 g/day	10–14 days	Directed therapy only (culture-confirmed susceptible organism). NOT for empiric pyelonephritis (fluoroquinolone or parenteral agent preferred empirically). Higher dose (1 g BD) needed for adequate renal tissue penetration.

Mandatory Clinical Notes Checklist — UTI:

When to prefer cefadroxil: Over cephalexin when BD dosing is specifically desired for adherence (e.g., working women with busy schedules, elderly on polypharmacy). Over fluoroquinolones for uncomplicated cystitis — stewardship advantage (reserve fluoroquinolones for more serious infections). The once-daily option is a unique advantage for highly compliant patients who prefer the simplest possible regimen.
When NOT to use:
- ⛔ Complicated UTI (structural abnormality, catheter-associated, male UTI, urosepsis) → broader agents
- ⛔ Suspected ESBL organism → nitrofurantoin (for cystitis) or carbapenem (for pyelonephritis)
- ⛔ Enterococcal UTI → no cephalosporin has enterococcal activity → use amoxicillin/ampicillin
- ⛔ Pseudomonas UTI → no activity
- ⛔ Empiric pyelonephritis first-line → fluoroquinolone or parenteral agent
- ⚠️ Indian community E. coli susceptibility to first-generation cephalosporins ~50–65% → always obtain urine culture
NLEM status: ✔ On NLEM 2022.
Time to response: Symptom improvement (frequency, dysuria) within 24–48 hours. If no improvement by 48–72 hours → check urine culture results and switch.
Treatment failure: Persistent symptoms at 72 hours; positive repeat culture → reassess organism susceptibility, imaging for structural cause, consider resistant organism.
Mandatory baseline:
- RECOMMENDED: Urine culture and sensitivity (midstream clean-catch) BEFORE starting — especially in India where first-generation cephalosporin resistance in E. coli is ~35–50%.
- MANDATORY (certain groups): Pregnant women, males, recurrent UTI, treatment failure.
Specialist initiation: Not required for uncomplicated cystitis. Complicated UTI, pyelonephritis, recurrent UTI → urology/nephrology referral.
Indian guideline source: API Textbook; ICMR Treatment Guidelines (2022); AIIMS Antibiotic Policy; IDSA/ESCMID UTI Guidelines (2011/2024 update).
Key safety warning: ⚠️ Always obtain urine culture in India before starting empiric first-generation cephalosporin for UTI. Indian E. coli resistance to these agents is substantially higher than in Western countries. Nitrofurantoin (resistance ~10–20%) remains the best empiric option for uncomplicated cystitis per ICMR.
Dose adjustment: Renal impairment → Part 4 (important — many UTI patients have coexisting CKD).

PRIMARY INDICATION 3: Acute Pharyngitis / Tonsillitis — Group A Streptococcus (GAS)

⚠️ THIS IS ARGUABLY CEFADROXIL’S MOST IMPORTANT CLINICAL NICHE — AND WHERE ITS ADVANTAGE OVER CEPHALEXIN IS MOST PRONOUNCED.

ℹ️ GAS pharyngitis treatment requires a mandatory 10-day course to eradicate the organism from the pharynx and prevent acute rheumatic fever (ARF). Any dosing simplification that improves 10-day course completion rates has direct public health impact on RHD prevention — and this is where cefadroxil shines. India has the world’s highest RHD burden.

Dosing — GAS Pharyngitis:

Regimen	Dose	Frequency	Maximum	Duration	Clinical Notes
Once-daily (OD) — preferred for adherence	1 g	OD (once daily)	Max 1 g per dose; Max 1 g/day	10 days	⭐ Unique advantage of cefadroxil. Multiple RCTs (Pichichero et al., 1991; Disney et al., 1992) demonstrate that cefadroxil 1 g OD × 10 days achieves GAS bacteriological eradication rates comparable to penicillin V QDS × 10 days and cephalexin BD × 10 days. The OD regimen offers the simplest possible dosing for a 10-day course — one capsule/tablet per day. Total pills for the entire course: 10 (vs 20 for cephalexin BD, 30 for amoxicillin TDS, 40 for penicillin V QDS).
Twice-daily (BD)	500 mg	BD (q12h)	Max 500 mg per dose; Max 1 g/day	10 days	Standard BD regimen — equivalent efficacy to the OD regimen. Total pills: 20. Preferred when the 1 g tablet/capsule is unavailable or when lower individual doses are desired.

ℹ️ OD dosing evidence for GAS pharyngitis — critical appraisal:

Pichichero ME, Gooch WM, Rodriguez W, et al. (1994): OD cefadroxil vs TDS penicillin V × 10 days — comparable eradication rates (~90–95% for cefadroxil OD, ~85–90% for penicillin V).
Disney FA, et al. (1992): Cefadroxil OD vs BD — equivalent outcomes.
These studies were conducted with adequate sample sizes and are the pharmacological basis for OD cefadroxil labelling for GAS pharyngitis in many international product inserts.
Why does OD dosing work despite the ~1.5-hour half-life? Beta-lactam bactericidal activity for GAS (which has a very low MIC — typically <0.12 mg/L for first-generation cephalosporins) requires fT>MIC for only a moderate fraction of the dosing interval. After a 1 g dose, serum levels exceed the GAS MIC for approximately 8–10 hours of the 24-hour interval — this appears sufficient for pharyngeal eradication in immunocompetent patients. Additionally, the post-antibiotic effect (PAE) of cephalosporins against streptococci extends the bactericidal window beyond the time that serum levels are measurably above MIC.

ℹ️ Comparison of total pill burden for 10-day GAS pharyngitis course:

Drug	Regimen	Total Pills (10-day course)	Empty Stomach Required?	Notes
Cefadroxil 1 g OD	⭐ Once daily	10	✔ No	Simplest regimen
Cefadroxil 500 mg BD	Twice daily	20	✔ No
Cephalexin 500 mg BD	Twice daily	20	✔ No	Evidence-supported BD cephalexin for GAS (Pichichero)
Amoxicillin 500 mg BD	Twice daily	20	✔ No	IAP/WHO first-line
Amoxicillin 500 mg TDS	Three times daily	30	✔ No	Traditional TDS amoxicillin dosing
Penicillin V 500 mg QDS	Four times daily	40	⚠️ Yes (empty stomach)	Traditional gold standard — but worst adherence profile

💡 Clinical implication for Indian RHD prevention: Every simplification of the 10-day pharyngitis treatment course has the potential to improve completion rates and reduce incident ARF. Cefadroxil 1 g OD is the simplest evidence-based oral regimen for GAS pharyngitis — 10 pills total, no food restriction, once daily. While amoxicillin remains the first-line agent (IAP/WHO/ICMR), cefadroxil OD is an excellent alternative when adherence is the primary concern.

Mandatory Clinical Notes Checklist — GAS Pharyngitis:

When to prefer cefadroxil: (a) When OD dosing is specifically desired for maximum adherence (school-going children, working adults, families with adherence challenges). (b) Non-anaphylactic penicillin allergy. © Treatment failure with amoxicillin or penicillin V (cephalosporin course for recurrence). (d) When the prescriber judges that the patient/family is unlikely to complete a BD or TDS regimen for a full 10 days. ℹ️ Amoxicillin remains the first-line agent per IAP and ICMR — cefadroxil is an excellent alternative, not the default first-line.
When NOT to use:
- ⛔ History of anaphylaxis to penicillin → avoid cephalosporins (cross-reactivity risk, though low ~1–2%) → use azithromycin 500 mg OD × 5 days
- ⛔ Suspected peritonsillar abscess or deep neck space infection → IV antibiotics + surgical drainage
- ⛔ Non-streptococcal pharyngitis (viral — the majority of cases) → no antibiotics
NLEM status: ✔ On NLEM 2022.
Time to response: Symptom improvement within 24–48 hours.
Treatment failure: Persistent symptoms at 72 hours; positive throat culture post-treatment; recurrence within 2–4 weeks.
Mandatory baseline:
- RECOMMENDED: Modified Centor / McIsaac Score. RADT for GAS if available. Throat culture (gold standard — but takes 24–48 hours).
- In resource-limited settings: Treat based on Centor score ≥3.
Specialist initiation: Not required. ENT referral for recurrent pharyngitis (≥7 episodes/year) or complications.
Indian guideline source: IAP Guidelines on GAS pharyngitis and ARF prevention; API Textbook; ICMR AMR guidelines; ICRP (Indian Council of Rheumatic Prevention). International: AHA, IDSA pharyngitis guidelines — all widely followed in India.
Key disease-specific safety warning: ⚠️ Do NOT shorten below 10 days — even with OD dosing. The OD regimen is not an excuse to shorten the course — it is a simplification of the daily regimen while maintaining the full 10-day course duration. Incomplete courses risk failure of GAS eradication → ARF risk. ⚠️ Counsel emphatically: “Take one capsule every day for 10 days — even if your throat feels completely better after day 2.”
Dose adjustment: Renal → Part 4.

PRIMARY INDICATION 4: Acute Otitis Media (AOM)

ℹ️ Same caveats as for cephalexin — amoxicillin is the undisputed first-line for AOM. Cefadroxil is a second-line alternative with the same borderline H. influenzae activity limitation as cephalexin. The BD dosing advantage is modest for AOM because the duration is shorter (5–10 days) and amoxicillin itself can be given BD.

Dosing — AOM (Adults):

Dose	Frequency	Maximum	Duration	Clinical Notes
500 mg–1 g	BD (q12h)	Max 1 g per dose; Max 2 g/day	5–7 days (mild-moderate AOM in adults); 10 days (severe or recurrent)	Second-line only. Use when amoxicillin is not tolerated (non-anaphylactic penicillin allergy) AND amoxicillin-clavulanate/cefuroxime axetil are unavailable or not tolerated.

Mandatory Clinical Notes Checklist — AOM:

When to prefer cefadroxil: Only when amoxicillin, amoxicillin-clavulanate, and cefuroxime axetil are all unavailable or not tolerated. Cefadroxil’s BD dosing does not confer a significant additional advantage for AOM since amoxicillin itself supports BD dosing. Cefadroxil’s borderline H. influenzae coverage limits its usefulness — for AOM treatment failure with amoxicillin, amoxicillin-clavulanate is preferred (covers beta-lactamase-producing H. influenzae and M. catarrhalis).
When NOT to use: ⛔ Suspected mastoiditis or intracranial complication → IV antibiotics; ⛔ CSOM; ⛔ History of penicillin anaphylaxis.
NLEM status: ✔ On NLEM.
Time to response: 48–72 hours.
Treatment failure: Switch to amoxicillin-clavulanate or cefuroxime axetil.
Mandatory baseline: Otoscopic examination.
Specialist initiation: Not required for uncomplicated AOM. ENT referral for complications.
Indian guideline source: IAP Guidelines; API Textbook; AAP AOM Guidelines (2013).
Key safety warning: ⚠️ Do not confuse AOM with otitis externa — different aetiology and treatment.
Dose adjustment: Renal → Part 4.

PRIMARY INDICATION 5: Oral Step-Down from IV Cefazolin

ℹ️ The cefazolin → cefadroxil IV-to-oral switch is a pharmacologically rational transition (both first-generation cephalosporins, identical spectrum). It is less commonly practised than cefazolin → cephalexin (which has more extensive evidence and broader familiarity) but is equally valid and offers the additional advantage of BD oral dosing.

Common clinical scenarios for cefazolin → cefadroxil step-down:

Original IV Indication	Cefadroxil Step-Down Dose	Duration of Oral Phase	Notes
SSTI (MSSA) treated with IV cefazolin	500 mg–1 g BD	Complete total 7–14 day course	Switch when afebrile ≥24–48 h, clinically improving, tolerating oral. BD dosing is a practical advantage for outpatient continuation.
Post-operative wound infection (MSSA)	500 mg–1 g BD	7–14 days total (IV + oral)	Directed therapy per wound culture.
UTI (pyelonephritis) treated with IV cefazolin	1 g BD	Complete total 10–14 day course	Directed therapy. Ensure organism is susceptible.
Bacteraemia (MSSA — uncomplicated, source controlled)	1 g BD (specialist decision)	Complete total course (specialist-directed)	⚠️ Oral step-down for MSSA bacteraemia is a specialist decision. Most ID specialists prefer cephalexin 1 g q6h (more frequent dosing → better fT>MIC for the higher MICs potentially encountered in bacteraemia). Cefadroxil 1 g BD provides fT>MIC for only ~50–60% of the 12-hour interval — this may be marginal for bacteraemia.

IV-to-oral switch criteria (same as for cephalexin):

✔ Afebrile ≥24–48 hours
✔ Clinical improvement
✔ Haemodynamically stable
✔ Tolerating oral intake
✔ No undrained collection
✔ Culture confirms susceptible organism (when available)
✔ Reliable patient for oral adherence

Mandatory Clinical Notes Checklist — IV-to-Oral Step-Down:

When to prefer cefadroxil over cephalexin for step-down: When BD dosing is specifically desired for outpatient continuation (patient being discharged home — BD dosing is simpler for home administration). For standard SSTI and UTI step-down, cefadroxil BD and cephalexin TDS are clinically equivalent.
When to prefer cephalexin INSTEAD of cefadroxil for step-down:
- Osteomyelitis / serious bone & joint infections → cephalexin 1 g q6h (4 g/day) provides better fT>MIC at high doses than cefadroxil 1 g BD (2 g/day maximum). Cefadroxil’s 2 g/day ceiling is pharmacokinetically marginal for osteomyelitis where sustained high trough levels are needed.
- MSSA bacteraemia → cephalexin q6h (more frequent dosing) preferred by most ID specialists.
- ⚠️ Cefadroxil should NOT be used for high-dose oral step-down in osteomyelitis — cephalexin is the more appropriate choice (higher daily dose achievable: 4 g/day vs 2 g/day).
NLEM status: ✔ Both cefazolin and cefadroxil on NLEM.
Time to response: Already responding (switch occurs AFTER response to IV).
Treatment failure after switch: Recurrence → reassess (inadequate absorption? undrained collection? resistance? need to return to IV?).
Mandatory baseline: Culture confirmation (RECOMMENDED).
Specialist initiation: For SSTI step-down → primary care can manage. For bacteraemia/osteomyelitis → ID specialist decision.
Indian guideline source: API Textbook; AIIMS Antibiotic Policy; ICMR guidelines support IV-to-oral switch.
Key safety warning: ⚠️ Ensure the patient will adhere to BD dosing for the full remaining duration. The advantage of BD dosing is lost if the patient skips even one daily dose (24-hour gap with no drug exposure).
Dose adjustment: Per renal function.

PRIMARY INDICATION 6: Bone and Joint Infections — MSSA (Oral Phase) — LIMITED ROLE

⚠️ IMPORTANT LIMITATION — CEFADROXIL IS NOT THE PREFERRED AGENT FOR OSTEOMYELITIS ORAL STEP-DOWN.

ℹ️ While cefadroxil is a first-generation cephalosporin with the same spectrum as cephalexin, its maximum daily dose of 2 g (1 g BD) is pharmacokinetically suboptimal for osteomyelitis, where high-dose oral therapy (4 g/day) is standard to achieve adequate bone tissue levels.

Why cephalexin is preferred over cefadroxil for osteomyelitis:

Parameter	Cephalexin	Cefadroxil
Maximum daily dose for osteomyelitis	4 g/day (1 g q6h) — well-established	2 g/day (1 g BD) — maximum labelled dose
Dosing frequency	q6h — more frequent = better fT>MIC at high MICs	q12h — less frequent = longer drug-free intervals
fT>MIC at 12-hour interval (MIC 4 mg/L)	Not applicable (dosed q6h)	~50–60% — marginal for serious infections
Evidence for osteomyelitis step-down	Established (OVIVA trial context, Indian ID practice)	Limited — no major trial data for osteomyelitis
Clinical preference (Indian ID practice)	✔ Preferred	⚠️ Not preferred

If cefadroxil MUST be used for bone/joint infection oral step-down (e.g., cephalexin genuinely unavailable — very uncommon in India):

Phase	Dose	Frequency	Maximum	Duration	Notes
Oral step-down	1 g	BD (q12h)	Max 1 g per dose; Max 2 g/day	3–6 weeks (total IV + oral)	⚠️ Suboptimal dosing for osteomyelitis. Use ONLY if cephalexin is truly unavailable. Monitor CRP weekly for treatment response. Consider adding probenecid to boost cefadroxil levels (off-label, specialist decision — limited evidence).

Mandatory Clinical Notes Checklist — Bone & Joint Infections:

When to prefer cefadroxil: ⚠️ Rarely preferred. Use only if cephalexin is genuinely unavailable. Cephalexin 1 g q6h is the standard oral first-generation cephalosporin for osteomyelitis step-down.
When NOT to use: ⛔ MRSA bone/joint infection; ⛔ Polymicrobial osteomyelitis; ⛔ TB spondylitis; ⛔ Vertebral osteomyelitis (pharmacokinetically insufficient at 2 g/day).
NLEM status: ✔ On NLEM.
Time to response: CRP should decline within 1 week.
Treatment failure: Rising CRP → reassess → switch to cephalexin q6h (higher dose achievable) or IV therapy.
Mandatory baseline: Blood cultures (MANDATORY); bone biopsy culture (RECOMMENDED); CRP + ESR; MRI; renal function.
Specialist initiation: ⚠️ MANDATORY. Orthopaedics + ID specialist.
Indian guideline source: API Textbook; AIIMS Antibiotic Policy; OVIVA trial (references cephalexin/flucloxacillin, not cefadroxil specifically).
Key safety warning: ⚠️ Do NOT use cefadroxil for osteomyelitis if cephalexin is available. The 2 g/day ceiling is a pharmacokinetic limitation. ⚠️ Always exclude TB osteomyelitis in India.
Dose adjustment: Renal → Part 4.

Secondary Indications — Adults Only (Off-label, if any)

SECONDARY INDICATION 1: Dental Infections (Periapical Abscess, Dental Cellulitis)

OFF-LABEL (not specifically labelled on many CDSCO product inserts)

OFF-LABEL but accepted standard practice — used in Indian dental practice.

ℹ️ Same limitations as cephalexin for dental infections — limited anaerobic coverage. Amoxicillin or amoxicillin-clavulanate are preferred first-line. Cefadroxil is an alternative for non-anaphylactic penicillin allergy, particularly when BD dosing improves compliance.

Dosing: 500 mg–1 g BD × 5–7 days. For mixed aerobic-anaerobic coverage, combine with metronidazole 400 mg TDS.

Evidence basis: Dental practice consensus; Indian Dental Association guidance. Expert opinion.

Level of evidence quality:Weak — consensus/expert practice.

Specialist only: Not required — can be prescribed by dentists and GPs.

SECONDARY INDICATION 2: Infective Endocarditis Prophylaxis — Dental Procedures (Penicillin-Allergic Patients)

OFF-LABEL for most Indian product inserts, but accepted standard practice — endorsed by AHA/ESC guidelines, widely followed in India.

Dosing:

Dose	Timing	Duration	Notes
2 g oral (single dose)	30–60 minutes before dental procedure (preferred: 60 min before)	Single dose only	⛔ Do NOT use in patients with history of penicillin anaphylaxis → use azithromycin 500 mg or clindamycin 600 mg. For non-anaphylactic penicillin allergy, cefadroxil is acceptable.

ℹ️ Same indications for IE prophylaxis as for cephalexin — prosthetic valves, prior IE, certain CHD, transplant valvulopathy. Same Indian context regarding RHD and IE prophylaxis debate (see cephalexin monograph for detailed discussion).

Evidence basis: AHA IE Prophylaxis Guidelines (Wilson et al., 2007/2021 update); ESC IE Guidelines; API Textbook.

Level of evidence quality:Moderate — guideline-endorsed; no RCTs for IE prophylaxis.

Specialist only: Cardiologist identifies patients; prescribing by dentist/GP.

SECONDARY INDICATION 3: Recurrent UTI Prophylaxis

OFF-LABEL for most product inserts.

OFF-LABEL but accepted standard practice — used in Indian urology/urogynaecology practice.

ℹ️ Cefadroxil’s longer half-life makes it pharmacokinetically slightly better suited for once-daily prophylactic dosing than cephalexin (which has a shorter half-life and may have more subtherapeutic periods during the overnight interval).

Dosing:

Strategy	Dose	Frequency	Duration	Notes
Continuous prophylaxis	250–500 mg	Once daily at bedtime	6–12 months	Low-dose prophylaxis. At bedtime to maximise overnight urinary concentration.
Post-coital prophylaxis	500 mg	Single dose within 2 hours after sexual intercourse	As needed	For women with UTI clearly associated with intercourse.

Evidence basis: IDSA/ESCMID guidelines; multiple RCTs supporting low-dose cephalosporin prophylaxis for recurrent UTI. Nitrofurantoin is preferred first-line prophylactic agent (ICMR).

Level of evidence quality:Strong — RCT evidence supports cephalosporin prophylaxis for recurrent UTI.

Specialist only: Urology/gynaecology guidance recommended for initiation.

SECONDARY INDICATION 4: Acne Vulgaris — Moderate (Alternative Oral Antibiotic)

OFF-LABEL

Dosing: 500 mg BD × 3 months (re-evaluate at 3 months). Do NOT exceed 6 months continuous.

When to use: Only when tetracyclines (doxycycline, minocycline) are contraindicated — pregnancy, children <8 years, allergy.

Evidence basis: Dermatology specialist practice; AAD guidelines list first-generation cephalosporins as second-line.

Level of evidence quality:Weak — no RCTs. Expert consensus.

Specialist only: Dermatologist guidance recommended.

SECONDARY INDICATION 5: Lactational Mastitis (Infective)

OFF-LABEL (not specifically labelled on most product inserts)

OFF-LABEL but accepted standard practice — used in Indian obstetric practice.

ℹ️ S. aureus (MSSA) is the most common cause. Cefadroxil provides effective MSSA coverage and is safe during breastfeeding.

Dosing: 500 mg BD × 7–10 days

When to start: Symptoms not improving after 12–24 hours of conservative measures (frequent feeding, warm compresses) OR moderate-severe presentation.

Compatibility with breastfeeding: ✔ Yes — safe. Continued breastfeeding from affected breast is encouraged.

Evidence basis: WHO Mastitis Guidelines; obstetric textbooks.

Level of evidence quality:Strong — WHO guideline-endorsed.

Specialist only: Not required — GP/obstetrician/paediatrician.

💡 Cefadroxil BD advantage for mastitis: A breastfeeding mother managing an infant + infection benefits from the fewest possible daily doses. BD dosing (morning + evening) is simpler than TDS/QDS — allowing the mother to focus on infant care and breastfeeding management.

SECONDARY INDICATION 6: UTI in Pregnancy (Second-Line Agent)

OFF-LABEL for some product inserts.

OFF-LABEL but accepted standard practice in India.

Dosing: 500 mg BD × 7 days (symptomatic UTI/cystitis in pregnancy); same for asymptomatic bacteriuria (ASB).

Safety: Former FDA Category B — safe in all trimesters. Extensive clinical experience. See Pregnancy (Part 4).

Evidence basis: FOGSI guidelines; ICMR; WHO; ACOG.

Level of evidence quality:Moderate — limited RCTs specific to cefadroxil in pregnancy UTI, but extensive clinical experience.

Specialist only: Not required — obstetrician/GP managing antenatal care.

SECONDARY INDICATION 7: Streptococcal Skin Infections — Erysipelas (Monotherapy)

OFF-LABEL as a specifically labelled indication on some inserts (many SSTI labels are broad; some are specific).

OFF-LABEL but accepted standard practice.

ℹ️ Erysipelas is almost exclusively caused by Group A Streptococcus (S. pyogenes) — for which cefadroxil has excellent activity.

Dosing: 500 mg–1 g BD × 5–10 days

ℹ️ Penicillin V is the traditional first-line for pure streptococcal erysipelas (narrowest effective spectrum), but cefadroxil BD provides better adherence than penicillin V QDS and covers the occasional MSSA co-infection.

Evidence basis: Dermatology/ID specialist practice. API Textbook.

Level of evidence quality:Weak — consensus/expert practice.

Specialist only: Not required.

PAEDIATRIC DOSING (Specialist Only)

General Notes:

Safety monitoring: Cefadroxil has an excellent safety profile in paediatric patients. No special paediatric-only monitoring is required beyond routine clinical assessment. Monitor for diarrhoea (especially in infants — risk of dehydration), allergic reactions (rash, urticaria), and oral thrush/diaper candidiasis with prolonged courses.
Minimum age/weight: Cefadroxil may be used from the neonatal period onwards (limited neonatal data — see below). There is no strict minimum weight threshold, but weight-based dosing (mg/kg) is mandatory for all children. Most clinical experience begins from 1 month of age.
Formulation suitability for children:
- ✔ Dry syrup/oral suspension (125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL) — widely available in India. Primary formulation for paediatric use.
- ✔ Paediatric drops (100 mg/mL) — available from select manufacturers; useful for infants.
- ✔ Dispersible tablets (250 mg, 500 mg) — select manufacturers; can be dispersed in water for children who cannot swallow capsules/tablets.
- Capsules (500 mg) — suitable for older children/adolescents who can swallow capsules (generally ≥8–10 years).
Palatability: Cefadroxil dry syrups are generally well-accepted. Most Indian manufacturers provide flavoured suspensions (orange, mixed fruit, strawberry). Palatability is comparable to cephalexin dry syrup. ℹ️ If a child refuses one brand’s flavour, switching to another manufacturer’s product often resolves the issue.
Age-specific PK differences:
- Neonates (<28 days): Half-life prolonged to 3–6 hours due to immature renal function. Lower doses per kg or extended intervals may be needed.
- Infants and young children (1 month – 2 years): Per-kg clearance is higher than adults — weight-based dosing in mg/kg inherently accounts for this.
- Children >2 years: PK approximates adult values on a per-kg basis.
- Adolescents ≥12 years or ≥40 kg: Use adult dosing.
Maximum dose ceiling: In all paediatric dosing, the calculated weight-based dose must NOT exceed the corresponding adult dose. Always state the adult ceiling alongside the mg/kg dose.

General Paediatric Dosing Framework:

Parameter	Standard Paediatric Dosing
Dose range	25–50 mg/kg/day
Usual dose (most indications)	30 mg/kg/day
Frequency	Divided BD (q12h) — or OD for GAS pharyngitis
Maximum single dose	1 g per dose
Maximum daily dose	2 g per day
Formulation	Dry syrup/oral suspension preferred for children <8–10 years
Take with or without food	✔ Either acceptable

Primary Indications — Paediatric (Approved / Standard in India)

PAEDIATRIC PRIMARY INDICATION 1: GAS Pharyngitis / Tonsillitis

⭐ This is the single most important paediatric indication for cefadroxil — and where its advantage over cephalexin and amoxicillin is most clinically impactful.

ℹ️ Why cefadroxil for paediatric GAS pharyngitis?
A 10-day course of antibiotics is mandatory for GAS eradication and ARF prevention. Compliance with 10-day courses is notoriously poor in children — studies show <50% completion rates for TDS/QDS regimens by day 7. Every reduction in daily dosing frequency improves course completion. Cefadroxil’s once-daily (OD) option — 10 pills/doses total for the entire course — is the simplest evidence-based oral regimen available.

💡 The “school-dose” problem: In India, children attending school cannot easily take a midday dose. TDS amoxicillin or QDS penicillin V requires a dose during school hours, which is frequently missed. Cefadroxil BD (morning + evening) or OD (evening only) eliminates the school-dose entirely.

Dosing Table — GAS Pharyngitis (Paediatric):

Regimen	Dose	Frequency	Max Single Dose	Max Daily Dose	Duration	Notes
Once-daily (OD) — preferred for adherence	30 mg/kg/day	OD (once daily)	1 g	1 g/day	10 days	⭐ Simplest regimen. Evidence from Pichichero et al. (1991, 1994): OD cefadroxil achieves GAS eradication rates of ~90–95%, comparable to penicillin V QDS and cephalexin BD. Total doses for entire course: 10.
Twice-daily (BD) — standard	30 mg/kg/day	BD (q12h — divided into 2 equal doses, i.e., 15 mg/kg per dose)	500 mg per dose	1 g/day	10 days	Equivalent efficacy to OD. Total doses: 20. Useful when the 30 mg/kg OD volume is impractically large for a young child.

Weight-based dosing examples (OD regimen — 30 mg/kg/day OD) using 250 mg/5 mL suspension:

Body Weight (kg)	Dose (mg)	Volume per Dose (250 mg/5 mL)	Frequency
5 kg	150 mg	3 mL	OD
8 kg	240 mg	~5 mL	OD
10 kg	300 mg	6 mL	OD
15 kg	450 mg	9 mL	OD
20 kg	600 mg	12 mL	OD
25 kg	750 mg	15 mL	OD
30 kg	900 mg	18 mL	OD
≥33 kg	1000 mg (cap at adult dose)	Use 500 mg capsule × 2 or 1 g tablet	OD

ℹ️ For children ≥25–30 kg receiving OD dosing, the suspension volume becomes large (≥15 mL). Consider switching to capsules (500 mg × 2) or a 1 g tablet if the child can swallow.

Mandatory Clinical Notes Checklist — Paediatric GAS Pharyngitis:

When to prefer cefadroxil: (a) OD dosing specifically desired — school-going children, families with adherence challenges, migrant/mobile families. (b) Non-anaphylactic penicillin allergy. © Treatment failure with amoxicillin (recurrence after a completed amoxicillin course). (d) Prescriber’s clinical judgement that the family is unlikely to complete a 10-day BD or TDS course. ℹ️ Amoxicillin remains the IAP/WHO first-line agent — cefadroxil is an excellent alternative, not the default.
When NOT to use: ⛔ History of penicillin/cephalosporin anaphylaxis → use azithromycin. ⛔ Suspected peritonsillar abscess. ⛔ Non-streptococcal pharyngitis (viral — most childhood pharyngitis is viral).
NLEM status: ✔ On NLEM 2022.
Time to response: 24–48 hours.
Treatment failure criteria: Persistent symptoms at 72 hours; positive throat culture post-treatment; recurrence within 2–4 weeks → consider clindamycin or amoxicillin-clavulanate for recurrence.
Baseline investigations: Modified Centor/McIsaac score. RADT for GAS if available. Throat culture (gold standard). In resource-limited settings: treat empirically with Centor ≥3.
Specialist initiation: Not required. Any paediatrician, GP, or PHC doctor can prescribe.
Indian guideline source: IAP Guidelines on Pharyngitis and ARF Prevention; ICRP (Indian Council of Rheumatic Prevention); API Textbook.
Key safety warning: ⚠️ Do NOT shorten below 10 days. The OD regimen is not a shortened course — it is a simplified daily regimen for a full 10-day course. Counsel parents emphatically: “Give one dose every day for 10 days — even if the child feels completely well after 2 days. Stopping early can cause rheumatic fever.”
Dose adjustment: Renal impairment → Part 4 (rare in children with pharyngitis but relevant in CKD patients).

PAEDIATRIC PRIMARY INDICATION 2: Skin and Soft Tissue Infections (SSTI)

Dosing Table — SSTI (Paediatric):

Severity	Dose	Frequency	Max Single Dose	Max Daily Dose	Duration	Notes
Mild (localised impetigo, minor wound infection, limited folliculitis)	25–30 mg/kg/day	BD (q12h — divided into 2 equal doses)	500 mg per dose	1 g/day	5–7 days	For very limited impetigo, topical mupirocin/fusidic acid may suffice.
Moderate (cellulitis, extensive impetigo, furunculosis, abscess post-drainage)	30–50 mg/kg/day	BD (q12h)	500 mg–1 g per dose	2 g/day	5–7 days (may extend to 10 days)	Higher end of dose range for deeper infections.
Moderate-to-severe (spreading cellulitis, large carbuncle)	50 mg/kg/day	BD (q12h)	1 g per dose	2 g/day	7–10 days	Maximum oral dosing. If systemic toxicity → IV cefazolin.

Weight-based dosing examples (30 mg/kg/day BD — i.e., 15 mg/kg per dose) using 250 mg/5 mL suspension:

Body Weight (kg)	Dose per Administration (mg)	Volume per Dose (250 mg/5 mL)	Frequency
5 kg	75 mg	1.5 mL	BD
8 kg	120 mg	2.5 mL	BD
10 kg	150 mg	3 mL	BD
15 kg	225 mg	4.5 mL	BD
20 kg	300 mg	6 mL	BD
30 kg	450 mg	9 mL	BD
≥40 kg	Adult dosing (500 mg)	Capsule	BD

Mandatory Clinical Notes Checklist — Paediatric SSTI:

When to prefer cefadroxil: BD dosing advantage — eliminates school-time dose. Preferred over cloxacillin QDS (empty-stomach requirement impractical in children) and over cephalexin TDS for adherence.
When NOT to use: ⛔ MRSA suspected (screen for CA-MRSA in recurrent SSTI). ⛔ Bite wounds → amoxicillin-clavulanate. ⛔ Neonatal skin infections (specialist management — often IV agents needed).
NLEM status: ✔ On NLEM.
Time to response: 48–72 hours. Mark cellulitis margins.
Treatment failure: No improvement at 72 hours → wound culture, consider MRSA, broader agent.
Baseline: Wound swab C/S (recommended). Blood glucose screening if recurrent SSTI in obese child.
Specialist initiation: Not required for mild-moderate SSTI.
Indian guideline source: IAP Guidelines; API Textbook.
Key safety warning: ⚠️ In recurrent paediatric SSTI in India, always consider: (a) underlying diabetes/prediabetes (increasingly common), (b) CA-MRSA (increasing in Indian metros), © nutritional deficiency/immunodeficiency, (d) hygiene/overcrowding factors.
Dose adjustment: Renal impairment → Part 4 (uncommon in children).

PAEDIATRIC PRIMARY INDICATION 3: Urinary Tract Infections (UTI)

ℹ️ UTI in children requires mandatory urine culture (clean-catch midstream or catheterised specimen). Empiric first-generation cephalosporin for paediatric UTI in India is reasonable only if local E. coli susceptibility data supports it (≥70% susceptibility threshold recommended). Nitrofurantoin is an alternative for cystitis in older children.

Dosing Table — UTI (Paediatric):

Condition	Dose	Frequency	Max Single Dose	Max Daily Dose	Duration	Notes
Acute uncomplicated cystitis	25–30 mg/kg/day	BD (q12h)	500 mg per dose	1 g/day	5–7 days	Directed therapy preferred (obtain urine C/S before starting).
Acute pyelonephritis (mild, outpatient — directed therapy only)	40–50 mg/kg/day	BD (q12h)	1 g per dose	2 g/day	10–14 days	⚠️ Oral outpatient therapy for paediatric pyelonephritis is appropriate ONLY if: (a) child >3 months old, (b) non-toxic appearing, © tolerating oral, (d) reliable family for follow-up. Otherwise → IV cefazolin/ceftriaxone initially.

Mandatory Clinical Notes Checklist — Paediatric UTI:

When to prefer cefadroxil: BD dosing advantage over cephalexin TDS for outpatient completion. Useful when urine culture confirms susceptible E. coli/K. pneumoniae/P. mirabilis.
When NOT to use: ⛔ Febrile UTI in infant <3 months → IV. ⛔ Toxic-appearing child → IV. ⛔ Suspected ESBL organism → nitrofurantoin (cystitis) or carbapenem (pyelonephritis). ⛔ Enterococcal UTI → amoxicillin/ampicillin.
NLEM status: ✔ On NLEM.
Time to response: Symptom improvement within 48 hours.
Treatment failure: Persistent fever at 48–72 hours → reassess, imaging (USG KUB — mandatory for first febrile UTI in children), switch antibiotics per C/S.
Baseline: ⚠️ MANDATORY: Urine culture and sensitivity BEFORE starting antibiotics. USG KUB recommended for all first febrile UTI in children. MCU/DMSA scan per paediatric nephrology protocol.
Specialist initiation: Uncomplicated cystitis → GP/paediatrician. Pyelonephritis or recurrent UTI → paediatric nephrologist.
Indian guideline source: IAP Guidelines on UTI in Children; API Textbook; Indian Paediatric Nephrology Group (IPNG) guidelines.
Key safety warning: ⚠️ All first-episode febrile UTI in children <2 years requires imaging workup (USG KUB at minimum) to rule out structural abnormality (VUR, PUJ obstruction). Do not simply treat and discharge.
Dose adjustment: Renal impairment → Part 4.

PAEDIATRIC PRIMARY INDICATION 4: Acute Otitis Media (AOM)

ℹ️ Same limitations as in adults — amoxicillin is first-line. Cefadroxil is second-line for non-anaphylactic penicillin allergy or amoxicillin intolerance.

Dosing Table — AOM (Paediatric):

Severity	Dose	Frequency	Max Single Dose	Max Daily Dose	Duration	Notes
Mild-moderate AOM	30 mg/kg/day	BD (q12h)	500 mg per dose	1 g/day	5–7 days (≥2 years); 10 days (<2 years or severe)	Second-line. Use when amoxicillin not tolerated.
Severe or recurrent AOM	40–50 mg/kg/day	BD (q12h)	1 g per dose	2 g/day	10 days	Higher end of dose range. Consider amoxicillin-clavulanate instead if H. influenzae/M. catarrhalis suspected (treatment failure).

Mandatory Clinical Notes Checklist — Paediatric AOM:

When to prefer cefadroxil: Only when amoxicillin is not tolerated (non-anaphylactic allergy, GI intolerance). BD dosing provides modest advantage over cephalexin TDS.
When NOT to use: ⛔ First-line (amoxicillin is superior for AOM). ⛔ Suspected mastoiditis or intracranial complication → IV antibiotics + urgent ENT referral.
NLEM status: ✔ On NLEM.
Time to response: 48–72 hours.
Treatment failure: No improvement at 72 hours → switch to amoxicillin-clavulanate or cefuroxime axetil.
Baseline: Otoscopic/pneumatic otoscopy examination. Tympanometry if available.
Specialist initiation: Not required. ENT referral for complications or recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months).
Indian guideline source: IAP Guidelines; AAP AOM Guidelines (2013).
Key safety warning: ⚠️ Observation without antibiotics is appropriate for mild AOM in children ≥2 years (watch-and-wait 48–72 hours) per AAP guidelines — applicable in Indian practice if reliable follow-up is possible.
Dose adjustment: Renal → Part 4.

PAEDIATRIC PRIMARY INDICATION 5: Oral Step-Down from IV Cefazolin

ℹ️ Same rationale as adult step-down. Common paediatric scenario: child admitted with cellulitis/abscess/UTI receiving IV cefazolin, transitioning to oral cefadroxil BD for outpatient completion.

Dosing:

Original IV Indication	Cefadroxil Step-Down Dose	Duration of Oral Phase	Notes
SSTI (MSSA)	30–50 mg/kg/day BD	Complete total 7–14 day course	Switch when afebrile ≥24 h, tolerating oral.
Pyelonephritis	40–50 mg/kg/day BD	Complete total 10–14 day course	Directed therapy per urine C/S.
Bone & joint infection	⚠️ See limitation note below	—	Cephalexin preferred (higher daily dose achievable).

⚠️ Same osteomyelitis limitation as in adults: Cefadroxil’s 2 g/day maximum is insufficient for paediatric osteomyelitis step-down, which typically requires cephalexin 100–150 mg/kg/day divided q6h (max 4 g/day). Do NOT use cefadroxil for osteomyelitis step-down if cephalexin is available.

Secondary Indications — Paediatric (Off-label, if any)

PAEDIATRIC SECONDARY INDICATION 1: Infective Endocarditis Prophylaxis — Dental Procedures

OFF-LABEL for most Indian product inserts. OFF-LABEL but accepted standard practice — endorsed by AHA/ESC guidelines, followed by Indian paediatric cardiologists.

Dosing:

Dose	Timing	Duration	Notes
50 mg/kg oral (single dose)	30–60 minutes before dental procedure	Single dose only	Max single dose: 2 g. ⛔ Do NOT use in patients with history of penicillin/cephalosporin anaphylaxis → azithromycin 15 mg/kg (max 500 mg) or clindamycin 20 mg/kg (max 600 mg).

Evidence basis: AHA IE Prophylaxis Guidelines (Wilson et al., 2007/2021 update); ESC; IAP/Paediatric Cardiology Guidelines.

Level of evidence quality: Moderate — guideline-endorsed; no paediatric RCTs for IE prophylaxis.

Specialist only: Paediatric cardiologist identifies patients; dentist/paediatrician prescribes the prophylactic dose.

PAEDIATRIC SECONDARY INDICATION 2: Recurrent UTI Prophylaxis

OFF-LABEL for most product inserts. OFF-LABEL but accepted standard practice — used by paediatric nephrologists.

Dosing:

Strategy	Dose	Frequency	Duration	Notes
Continuous prophylaxis	10–15 mg/kg	Once daily at bedtime	3–12 months (specialist-directed)	Low-dose prophylaxis. At bedtime to maximise overnight urinary concentration. Max prophylactic dose: 500 mg/day.

ℹ️ Nitrofurantoin (1–2 mg/kg/day) and TMP-SMX (1–2 mg/kg/day TMP component) are the more commonly used prophylactic agents in India. Cefadroxil is an alternative when these are not tolerated or are contraindicated.

Evidence basis: IAP/IPNG guidelines; RIVUR trial (supported antibiotic prophylaxis for VUR-associated UTI in children — used TMP-SMX, but cephalosporins are accepted alternatives). Multiple observational studies.

Level of evidence quality: Moderate — adult RCTs with paediatric extrapolation; paediatric observational data.

Specialist only: ⚠️ Paediatric nephrologist guidance recommended for initiation. Duration and discontinuation should be specialist-directed.

Neonatal Dosing:

ℹ️ Neonatal use — limited data. Use under neonatologist supervision.

Gestational Age	Dose	Frequency	Notes
Term neonates (≥37 weeks GA)	25–30 mg/kg/day	BD (q12h — 12.5–15 mg/kg per dose)	Half-life prolonged to 3–6 hours. Oral absorption reliable from approximately 1 week of age in term neonates.
Preterm neonates (<37 weeks GA)	Data limited	—	⚠️ No established preterm neonatal dosing. Avoid oral cefadroxil in preterm neonates unless specifically directed by a neonatologist. Parenteral agents (ampicillin, cefotaxime) are standard for neonatal infections.

ℹ️ Cefadroxil is rarely the drug of choice in neonatal infections. Neonatal sepsis protocols use IV ampicillin + gentamicin (early-onset) or IV vancomycin + cefotaxime/meropenem (late-onset). Oral cefadroxil may be considered for step-down therapy in select neonatal UTI cases under neonatologist supervision.

MISSED DOSE / DELAYED DOSE GUIDANCE

For twice-daily (BD — q12h) dosing:

If a dose is remembered within 6 hours of the scheduled time → take the missed dose immediately. Then take the next dose at the regular time.
If more than 6 hours have passed → skip the missed dose. Take the next dose at the regular scheduled time.
⛔ Never double up — do not take two doses at once to make up for a missed dose.

For once-daily (OD — q24h) dosing (GAS pharyngitis):

If a dose is remembered within 12 hours of the scheduled time → take the missed dose immediately. Then take the next dose at the regular time the following day.
If more than 12 hours have passed → skip the missed dose. Take the next dose at the regular scheduled time the next day.
⛔ Never double up.

💡 Practical tip for clinicians: For the 10-day GAS pharyngitis course, counsel parents: “If you miss today’s dose and remember at bedtime, give it then. If you only remember the next morning, skip the missed dose and continue with today’s dose. Add one extra day to the end of the course to make up for the missed day.” This “extend-by-one-day” approach is a pragmatic clinical practice supported by expert consensus — it ensures the child receives a full 10 doses even if one is missed.

Prolonged non-adherence / drug holiday guidance:

Cefadroxil does NOT have rebound effects upon discontinuation or resumption.
If multiple consecutive doses are missed (≥2–3 days of the course), the antibiotic course becomes ineffective. The infection may not be adequately treated.
- For SSTI/UTI: Restart the course from the beginning if significant doses were missed and infection has not resolved.
- For GAS pharyngitis: If ≥3 consecutive doses are missed during the 10-day course, restart the full 10-day course from day 1 — incomplete GAS eradication risks ARF.
No re-titration needed — cefadroxil can be resumed at the full dose immediately.
No withdrawal syndrome or immunogenicity concerns.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

ℹ️ Cefadroxil is an oral-only drug. No IV/IM formulations exist. This section covers dry syrup reconstitution and oral administration notes.

Reconstitution — Dry Syrup / Oral Suspension (Powder for Reconstitution):

Parameter	Details
Diluent	Freshly boiled and cooled water (or clean potable water if boiled water is unavailable). Do NOT use hot water.
Volume of water to add	As specified on the individual product label — varies by manufacturer and bottle size. Typically: 30 mL bottle → add water up to the mark on the bottle; 60 mL bottle → add water up to the mark. Always check the label.
Method	(1) Tap the bottle to loosen the powder. (2) Add approximately half the required volume of water. (3) Shake well until all powder is dissolved and no lumps remain. (4) Add the remaining water up to the mark. (5) Shake again.
Final concentration	As labelled: 125 mg/5 mL, 250 mg/5 mL, or 500 mg/5 mL (depending on product).
Appearance after reconstitution	Off-white to pale yellow suspension. Slight colour variation between manufacturers is normal.

Stability After Reconstitution:

Condition	Shelf Life
Refrigerated (2–8°C)	14 days — this is the standard for most manufacturers. Verify individual product label.
Room temperature (25°C)	7 days — most manufacturers recommend refrigeration. In Indian summer conditions (>30°C ambient temperature), room-temperature stability may be shorter. ⚠️ Refrigeration is strongly recommended.
Protected from light?	Recommended — store in the original bottle (opaque container).

⚠️ Indian practical note: In areas without reliable refrigeration (rural PHC, tribal areas, urban slums), counsel families to keep the reconstituted suspension in the coolest part of the house (away from direct sunlight and heat sources). Consider using the 7-day room-temperature limit rather than 14 days. If refrigeration is completely unavailable and the infection course is >7 days, a fresh bottle may need to be dispensed and reconstituted at the midpoint.

Administration of Each Dose from Reconstituted Suspension:

Shake the bottle well before each dose (drug settles on standing).
Use the measuring cup, dosing syringe, or calibrated spoon provided with the product. ⛔ Do NOT use household teaspoons/tablespoons — they are inaccurate and cause dosing errors.
Administer directly into the child’s mouth using the dosing syringe for infants (reduces spillage).
May be mixed with a small amount of milk, juice, or water immediately before administration if the child resists the taste — but give the full mixed volume to ensure the entire dose is received.

Oral Administration Notes — Capsules and Tablets:

Form	Instructions
Capsules (500 mg)	Swallow whole with a full glass of water. Do NOT open, crush, or chew.
Film-coated tablets (500 mg, 1 g)	Swallow whole with water. Do NOT crush or chew.
Dispersible tablets (250 mg, 500 mg)	Drop in approximately 10–15 mL of water. Allow to disperse (1–2 minutes). Stir and administer the entire suspension. Rinse the cup and administer the rinse to ensure full dose delivery.

Take with or without food: ✔ Either acceptable. Taking with food may reduce GI upset (nausea). No significant effect on absorption.

Enteral (NG/OG/PEG) tube compatibility: Cefadroxil suspension may be administered via enteral feeding tubes. Flush the tube with 10–20 mL of water before and after administration. Dispersible tablets dissolved in water may also be used via enteral tubes. Capsule contents should NOT be emptied into feeding tubes (powder may clog the tube).

Storage — Unopened Products:

Form	Storage
Dry syrup powder (before reconstitution)	Room temperature (below 30°C). Protect from moisture.
Capsules and tablets	Room temperature (below 30°C). Protect from moisture. Store in original packaging.
Paediatric drops (before reconstitution)	Room temperature (below 30°C).

RENAL ADJUSTMENT

ℹ️ Cefadroxil is primarily renally eliminated (~90–95% unchanged in urine). Dose adjustment is mandatory in significant renal impairment. Accumulation without adjustment can lead to neurotoxicity (seizures, encephalopathy — rare but reported with cephalosporins at very high serum levels) and increased GI adverse effects.

eGFR formula note: Original cefadroxil dosing studies and product insert recommendations use Cockcroft-Gault CrCl (mL/min). This table uses CrCl (Cockcroft-Gault) as the primary metric. eGFR (CKD-EPI) values are generally comparable for clinical purposes, but may diverge significantly in elderly patients with low muscle mass (CKD-EPI overestimates true GFR relative to Cockcroft-Gault in this group). In elderly patients, use Cockcroft-Gault CrCl for dose adjustment when possible.

Adult Renal Dosing Adjustment:

CrCl (mL/min)	Dose	Interval	Notes
>50	No adjustment needed	Standard BD (q12h) or OD (pharyngitis)	Full standard dosing.
25–50	500 mg	q12h (BD)	If the standard dose was 1 g BD, reduce to 500 mg BD. If the standard dose was 500 mg BD, maintain 500 mg BD. Some references allow 1 g q24h as an alternative. Monitor for adverse effects.
10–25	500 mg	q24h (OD)	Single daily dose. Adequate for most indications at this level of renal function due to prolonged half-life (4–8 hours at this CrCl range).
<10 (non-dialysis)	500 mg	q36h	Half-life prolonged to 8–20+ hours. Drug accumulates significantly. Monitor for neurotoxicity (confusion, myoclonus, seizures).
Haemodialysis	Loading dose: 1 g before first HD session. Then 500 mg after each HD session.	Post-HD dosing	Cefadroxil is moderately dialysable (~30–40% removed per 4-hour HD session). Supplemental dose required post-HD. On non-HD days: 500 mg q36h (as for CrCl <10).
Peritoneal dialysis (CAPD)	500 mg	q36h	Limited data. Peritoneal clearance of cefadroxil is low (~10–15%). Dose as for CrCl <10 mL/min.
CRRT	500 mg	q12h (BD)	Limited data. CRRT provides continuous clearance — likely closer to CrCl 25–50 range. Monitor drug levels if feasible (not routinely available). Adjust based on clinical response and residual renal function.

Paediatric Renal Dosing Adjustment:

CrCl (mL/min/1.73 m²)	Dose Adjustment	Notes
>50	No adjustment	Standard weight-based dosing.
25–50	Reduce dose by ~50% OR extend interval to q24h	e.g., if standard is 15 mg/kg BD → give 15 mg/kg OD or 7.5 mg/kg BD.
10–25	Reduce dose and extend interval: ~15 mg/kg q24h	Monitor closely.
<10	~15 mg/kg q36h	Specialist supervision.

ℹ️ Paediatric CrCl estimation: Use the Schwartz formula (updated bedside Schwartz, 2009) for paediatric eGFR estimation: eGFR = (0.413 × height in cm) / serum creatinine (mg/dL).

Augmented Renal Clearance (ARC):

Cefadroxil is an oral-only drug and is unlikely to be the agent of choice in patients with ARC (typically ICU patients where parenteral agents are used). ARC (CrCl >130 mL/min) would theoretically increase cefadroxil clearance and lower drug levels, but this is not a clinically relevant scenario for cefadroxil prescribing. If oral cefadroxil is being used in a young trauma/burn patient with ARC for step-down therapy, consider cephalexin q6h instead (more frequent dosing mitigates the effect of increased clearance).

Source: CDSCO product insert (multiple manufacturers); Goodman & Gilman, 14th Edition; Drug Prescribing in Renal Failure (Aronoff et al.).

HEPATIC ADJUSTMENT

No hepatic dose adjustment required.

Cefadroxil is NOT metabolised by the liver. It undergoes no hepatic biotransformation, has no CYP450 involvement, and produces no active metabolites. It is excreted >90% unchanged in the urine.

Hepatic Status	Dose Adjustment	Notes
Mild impairment (Child-Pugh A)	No adjustment
Moderate impairment (Child-Pugh B)	No adjustment
Severe impairment (Child-Pugh C)	No adjustment	Even in decompensated cirrhosis, cefadroxil does not require hepatic dose adjustment. However, cirrhotic patients often have concurrent renal impairment (hepatorenal syndrome) — check renal function and adjust for CrCl if needed.
Concurrent hepatotoxins	No additional hepatic concern from cefadroxil	Cefadroxil is NOT hepatotoxic. Co-administration with rifampicin, INH, pyrazinamide, methotrexate, or antiretrovirals does not require additional LFT monitoring specifically for cefadroxil.

ℹ️ This is one of cefadroxil’s pharmacological strengths — identical to cephalexin. In cirrhotic patients requiring antibiotic therapy for SBP or SSTI, cefadroxil (if the indication is appropriate) can be used without hepatic concern, adjusting only for renal function.

⚠️ Hypoalbuminaemia note: Cefadroxil has low protein binding (~20%), so hypoalbuminaemia (common in cirrhosis) does NOT significantly alter free drug levels. No protein-binding-related dose adjustment needed.

CONTRAINDICATIONS

⛔ 1. Known anaphylaxis or severe hypersensitivity to cefadroxil or any cephalosporin.

Includes: anaphylaxis (type I hypersensitivity — urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS) attributed to any cephalosporin.
Cephalosporin cross-reactivity within the class: Cross-reactivity between cephalosporins is side-chain dependent, not uniform across the class. However, if a patient had anaphylaxis to ANY cephalosporin, avoid ALL cephalosporins unless the specific side-chain relationship is known and the non-cross-reactive cephalosporin has been confirmed safe by an allergist.
Clinical rationale: Re-exposure after anaphylaxis risks fatal anaphylaxis.

⛔ 2. Known anaphylaxis to penicillins — NEAR-ABSOLUTE contraindication (with nuance).

Cross-reactivity between penicillins and cephalosporins: Historically estimated at ~10% (older literature, confounded by impurities). Current evidence: true cross-reactivity rate is ~1–2% for cephalosporins overall, and is primarily R1 side-chain-dependent, not beta-lactam ring-dependent.
Cefadroxil-specific cross-reactivity: Cefadroxil’s side chain (para-hydroxyphenylglycine) is structurally similar to the side chains of amoxicillin and ampicillin (both contain phenylglycine or hydroxyphenylglycine moieties). Therefore, the cross-reactivity risk between amoxicillin/ampicillin and cefadroxil may be HIGHER than average (~1–2% overall) — potentially ~5–10% based on shared R1 side-chain structure. This is the same concern as for cephalexin (which also has a phenylglycine side chain).
Clinical guidance:
- ⛔ If the patient had confirmed anaphylaxis to amoxicillin or ampicillin specifically → avoid cefadroxil (shared side chain → higher cross-reactivity risk). Use a structurally dissimilar cephalosporin (e.g., cefuroxime — different R1 side chain) under allergist supervision, or use a non-beta-lactam alternative.
- ⚠️ If the patient had anaphylaxis to a non-aminopenicillin (e.g., penicillin V, penicillin G, flucloxacillin) → cefadroxil may be used with caution (different side chains → lower cross-reactivity risk, estimated ~1%). Administer the first dose under observation (30–60 minutes) in a facility with anaphylaxis management capability.
- If the patient had non-severe penicillin allergy (maculopapular rash, GI upset) → cefadroxil can generally be used. Observe for 30 minutes after first dose.

⛔ 3. History of cephalosporin-induced SJS, TEN, or DRESS.

Re-exposure to any cephalosporin after these severe cutaneous adverse reactions is absolutely contraindicated. These reactions are not necessarily side-chain-specific and may represent broader beta-lactam hypersensitivity.

CAUTIONS

⚠️ High-priority cautions:

⚠️ 1. Renal impairment (CrCl <50 mL/min)

Cefadroxil accumulates in renal impairment → increased risk of adverse effects (GI intolerance, neurotoxicity at extreme levels).
Monitoring required: Estimate CrCl/eGFR before starting. Dose adjustment mandatory — see Renal Adjustment table above.
Special concern in elderly patients: “Normal” serum creatinine may mask CrCl <50 mL/min in elderly patients with low muscle mass. Always calculate CrCl using Cockcroft-Gault.

⚠️ 2. History of Clostridioides difficile infection (CDI) or antibiotic-associated colitis

All cephalosporins carry a risk of CDI, though first-generation cephalosporins are considered lower risk than third-generation cephalosporins and fluoroquinolones.
Monitoring required: Monitor for diarrhoea during and up to 8 weeks after completing therapy. If ≥3 loose stools/day develop during or after cefadroxil therapy, consider CDI. Send stool for C. difficile toxin assay. Discontinue cefadroxil if CDI is confirmed. Do NOT use anti-motility agents (loperamide) in suspected CDI.
Patients with prior CDI episodes are at higher risk of recurrence with any antibiotic exposure.

⚠️ 3. History of seizure disorder

Cephalosporin-induced neurotoxicity (including seizures) is a recognised class effect, primarily with parenteral cephalosporins at high doses and in renal impairment. It is rare with oral cefadroxil at standard doses. However, in patients with pre-existing seizure disorder AND renal impairment, cefadroxil accumulation could theoretically lower the seizure threshold.
Monitoring required: Use with caution in patients with both seizure disorder and significant renal impairment (CrCl <25 mL/min). Adjust dose per renal table.

⚠️ 4. Non-anaphylactic penicillin allergy (maculopapular rash, urticaria — non-severe)

Cross-reactivity risk is low (~1–2% overall; slightly higher for amoxicillin/ampicillin-specific allergy due to shared side chain — see Contraindications).
Action required: Cefadroxil may be used. Observe the patient for 30 minutes after the first dose in a facility with anaphylaxis management capability. Counsel the patient about signs of allergic reaction (rash, swelling, difficulty breathing).

Standard cautions:

5. Prolonged antibiotic courses (>14 days)

Risk of superinfection: Oral/vaginal candidiasis (thrush, vaginal yeast infection), antibiotic-associated diarrhoea (non-CDI).
Monitor for oral thrush (white patches in mouth), vaginal symptoms (itching, discharge), persistent diarrhoea.
Consider prophylactic oral nystatin or fluconazole for patients on prolonged courses (>2 weeks) who are immunocompromised or have a history of recurrent candidiasis.

6. Diabetes mellitus

Cefadroxil dry syrup contains sucrose (most Indian formulations). The quantity of sucrose per dose is small and unlikely to significantly affect blood glucose in most diabetic patients, but should be noted for patients on strict carbohydrate-controlled diets or brittle diabetes.
ℹ️ Capsules and tablets are sucrose-free.
Cephalosporins can cause false-positive urine glucose with copper-reduction methods (Benedict’s test, Clinitest). Use glucose oxidase-based methods (Diastix, glucometer) for urine glucose testing in patients on cefadroxil. This is a class effect of cephalosporins.

7. False-positive direct Coombs’ test

Cephalosporins can cause a positive direct antiglobulin test (DAT / direct Coombs’ test) without haemolytic anaemia. This is a class effect. Clinically significant haemolytic anaemia is extremely rare.
Relevant in: neonates (Coombs’ testing for HDN), pre-transfusion testing, autoimmune haemolytic anaemia workup.
Inform the blood bank/haematology team if the patient is on cefadroxil and requires cross-matching or Coombs’ testing.

8. Inflammatory bowel disease (IBD — ulcerative colitis, Crohn’s disease)

Any antibiotic use can disrupt the gut microbiome and potentially trigger IBD flares. Use cefadroxil in IBD patients only when clearly indicated. Monitor for increased stool frequency or bloody stools.

9. Concomitant use of probenecid

Probenecid blocks renal tubular secretion of cefadroxil via OAT1/OAT3 → increased serum levels and prolonged half-life. This is an intentional drug interaction in the (rarely used) cefadroxil + probenecid FDC. If probenecid is co-prescribed for gout, monitor for cefadroxil-related adverse effects.

10. Concomitant use of potent nephrotoxins

Aminoglycosides (gentamicin, amikacin), vancomycin, amphotericin B, NSAIDs (chronic use), contrast media — when co-administered with cefadroxil, may increase the risk of nephrotoxicity and subsequent cefadroxil accumulation. Monitor renal function more frequently.

PREGNANCY

Overall safety statement: Cefadroxil is considered compatible with use in pregnancy when clinically indicated. It is one of the safest antibiotics available for pregnant women, with extensive clinical experience spanning several decades.

Former US-FDA Pregnancy Category: B (animal reproduction studies have not demonstrated fetal risk; adequate well-controlled studies in pregnant women are lacking, but clinical experience supports safety). The FDA category system was retired in 2015 but remains a useful reference point.

Parameter	Details
Teratogenicity	No evidence of teratogenicity in animal studies or in extensive human clinical experience. No teratogenic signal in large pregnancy registries or epidemiological studies. Cefadroxil is NOT associated with congenital malformations in any trimester.
Teratogenicity window	Not applicable — no teratogenic risk identified in any developmental window (first trimester organogenesis period or later trimesters).
First trimester	✔ May be used. No increased risk of major malformations reported. Pharmacokinetically, drug levels are adequate at standard doses in the first trimester (plasma volume expansion and GFR increase are less pronounced than later trimesters).
Second trimester	✔ May be used. Plasma volume expansion begins — drug levels may be slightly lower than in non-pregnant patients, but clinically adequate for most indications (especially UTI, where urinary concentrations remain very high).
Third trimester	✔ May be used. GFR increases by ~50% and plasma volume by ~40–50% → cefadroxil clearance is increased and serum levels may be ~20–30% lower than in non-pregnant patients. For UTI (most common pregnancy indication), urinary concentrations remain therapeutic. For non-UTI indications in the third trimester, consider using the higher end of the dose range (1 g BD) to compensate for increased clearance. No adverse neonatal effects (no neonatal respiratory depression, no withdrawal, no jaundice) attributed to cefadroxil.
Peripartum/delivery	No dose adjustment needed at delivery. No adverse effects on uterine contractility or labour. No increased risk of postpartum haemorrhage.

PK changes in pregnancy — clinical implications:

PK Parameter	Change in Pregnancy	Clinical Implication
Volume of distribution	Increased (plasma volume ↑ 40–50%)	Lower peak serum concentrations
GFR	Increased (~50%)	Increased renal clearance → lower serum levels but very high urinary concentrations preserved
Half-life	Slightly shortened (~1.0–1.3 h vs ~1.5 h non-pregnant)	Shorter drug exposure per dose; BD dosing still adequate for most indications
Protein binding	No significant change (~20% bound)	Free drug fraction unchanged
AUC	Reduced by ~20–30% compared to non-pregnant	For UTI: compensated by high urinary drug concentrations. For SSTI/pharyngitis: consider higher dose range (1 g BD).

Common indications in pregnancy:

Indication	Dose	Duration	Notes
Asymptomatic bacteriuria (ASB) — screening positive	500 mg BD	5–7 days	⚠️ MANDATORY to treat ASB in pregnancy — untreated ASB progresses to pyelonephritis in ~20–40% of pregnant women. Cefadroxil is a second-line agent; nitrofurantoin is first-line per ICMR (avoid nitrofurantoin at term — theoretical risk of neonatal haemolysis).
Acute cystitis in pregnancy	500 mg BD	5–7 days	Directed therapy preferred (urine C/S before starting).
Acute pyelonephritis (mild, outpatient — rare in pregnancy)	1 g BD	10–14 days	⚠️ Most pregnant women with pyelonephritis require hospitalisation and IV antibiotics (ceftriaxone or cefazolin). Outpatient oral therapy ONLY if: early/mild, non-toxic, tolerating oral, reliable follow-up, ≥second trimester.
GAS pharyngitis in pregnancy	1 g OD or 500 mg BD	10 days	Safe and effective. Same regimen as non-pregnant adults.
SSTI (MSSA) in pregnancy	500 mg–1 g BD	5–10 days	Preferred over cloxacillin/flucloxacillin (better adherence, no empty-stomach requirement — particularly advantageous in pregnancy where nausea is common).

Preferred alternatives in Indian obstetric practice (for indications where cefadroxil might be considered):

Indication	First-line Agent (Indian practice)	Cefadroxil Status
UTI in pregnancy (cystitis, ASB)	Nitrofurantoin (avoid at term) OR cephalexin	Second-line alternative — equivalent efficacy to cephalexin; BD dosing advantage
Pyelonephritis in pregnancy	IV ceftriaxone or IV cefazolin (hospitalised)	Step-down to oral cefadroxil after clinical improvement
GAS pharyngitis in pregnancy	Amoxicillin 500 mg BD × 10 days	Alternative — OD option is unique advantage
SSTI (MSSA) in pregnancy	Cephalexin or cefadroxil	Either acceptable; cefadroxil preferred for adherence

What to monitor (mother and fetus):

Maternal: Standard clinical monitoring. No cefadroxil-specific maternal monitoring required beyond routine antenatal care. Monitor for clinical response (UTI symptoms, pharyngitis, SSTI).
Fetal: No cefadroxil-specific fetal monitoring required. Standard antenatal ultrasound schedule is sufficient.
Neonate (post-delivery, if cefadroxil was used peripartum): No specific neonatal observation for cefadroxil exposure. No neonatal withdrawal, respiratory depression, or jaundice attributed to cefadroxil.

Pre-conception counselling: Not required. Cefadroxil does not require washout before conception. No pre-conception planning needed.

Contraception during use: Not required. Cefadroxil is pregnancy-safe.

Pregnancy Prevention Programme / Registry: Not applicable. No mandatory pregnancy prevention programme or pregnancy exposure registry for cefadroxil.

Fertility Effects:
No known effect on male or female fertility. Cefadroxil does not affect spermatogenesis, ovulation, or reproductive hormone levels. No washout period before planned conception is necessary.

ℹ️ Comparison with cephalexin in pregnancy: Cefadroxil and cephalexin have identical pregnancy safety profiles. The choice between them in pregnancy follows the same principles as in non-pregnant patients — cefadroxil for BD dosing convenience, cephalexin for wider availability and lower cost. The BD dosing advantage may be particularly appreciated by pregnant women experiencing nausea who may find fewer daily doses easier to tolerate.

Indian guideline source: FOGSI Guidelines on UTI in Pregnancy; ICMR Antimicrobial Treatment Guidelines (2022); API Textbook of Medicine; WHO Model Prescribing Information; IAP Neonatology Guidelines (for neonatal safety of maternal antibiotics).

LACTATION

Compatible with breastfeeding: ✔ YES — safe.

Parameter	Details
Excreted in breast milk?	Yes — small amounts are excreted in breast milk.
Relative Infant Dose (RID)	Estimated ~0.8–1.3% of the maternal weight-adjusted dose. This is well below the 10% threshold that is generally considered the upper limit of acceptability for breastfeeding compatibility.
Drug levels in milk	Low. Peak milk concentrations of approximately 0.1–0.3 mcg/mL have been reported after standard maternal doses.
Milk-to-plasma (M/P) ratio	~0.009–0.019 — very low transfer into milk.
Active metabolites in milk	Not applicable — cefadroxil has no active metabolites.
Safety classification	Compatible with breastfeeding — widely used in lactating women worldwide without adverse infant outcomes. Listed as compatible by LactMed (NIH), WHO, and multiple Indian obstetric references.

What to monitor in the breastfed infant:

✔ Diarrhoea (mild, self-limited — most common potential effect; due to small amounts of drug altering infant gut flora)
✔ Oral thrush / diaper candidiasis (due to disruption of normal flora)
✔ Allergic reactions (rash, urticaria — very rare; consider if the infant has a known beta-lactam allergy)
✔ Feeding difficulties (irritability, refusal to feed — very rare)

ℹ️ In the vast majority of cases, breastfed infants of mothers taking cefadroxil show NO adverse effects. The low RID and minimal milk transfer make significant infant exposure extremely unlikely.

Timing advice: Not required. Because the RID is very low (<2%), there is no need to time doses relative to feeds. The mother can take cefadroxil at any time without adjusting breastfeeding schedule.

Effect on milk production: No known effect. Cefadroxil does not suppress or enhance milk production (no galactorrhoea, no lactation suppression).

Temporary incompatibility guidance: Not applicable — cefadroxil is fully compatible with breastfeeding. No need to withhold breastfeeding, express and discard milk, or delay feeds.

Preferred alternatives (if cefadroxil is not recommended for another reason):

Cephalexin — identical lactation safety profile, same low RID
Amoxicillin — compatible with breastfeeding
Penicillin V — compatible with breastfeeding

💡 Clinical pearl — lactational mastitis: Cefadroxil is an excellent choice for infective lactational mastitis (S. aureus — MSSA). It provides effective MSSA coverage, is safe for the breastfed infant, allows continued breastfeeding from the affected breast (which is recommended for mastitis resolution), and BD dosing minimises medication burden for a mother managing an infant. This is arguably one of cefadroxil’s most practical clinical niches.

Indian guideline source: LactMed (NIH); FOGSI; WHO Mastitis Guidelines; API Textbook.

ELDERLY

Definition: For this formulary, elderly is defined as ≥60 years (consistent with Indian Census and National Programme for Health Care of the Elderly definitions).

General principles:
Cefadroxil is safe and well-tolerated in elderly patients. The primary concern is age-related decline in renal function, which reduces cefadroxil clearance and prolongs its half-life. The drug itself does not have intrinsic properties that make it more dangerous in the elderly (no significant CNS depression, no postural hypotension, no anticholinergic effects, no QT prolongation).

Parameter	Guidance
Starting dose	Standard adult dose (500 mg BD) is acceptable if eGFR/CrCl >50 mL/min. If CrCl 25–50 mL/min, start at 500 mg BD (no further reduction needed at this range for cefadroxil, as this IS the reduced dose — see Renal Adjustment table). If CrCl <25 mL/min, reduce further per renal table.
Titration	Not applicable — cefadroxil is a fixed-dose antibiotic, not titrated.
Dose adjustment for age alone	No adjustment required for age per se. Adjustment is based entirely on renal function (CrCl/eGFR).
Half-life in elderly	Prolonged proportionally to renal function decline. In a 75-year-old with CrCl ~40 mL/min, half-life may be ~2.5–4 hours (vs ~1.5 hours in young adults). In an elderly patient with CrCl <10 mL/min, half-life may be 10–20+ hours.

⚠️ Critical concern — “normal” creatinine masking renal impairment:

This is the single most important practical point for prescribing cefadroxil in the elderly in India.

Many elderly patients (especially thin, sarcopenic individuals — common in the Indian elderly population) have a serum creatinine of 0.8–1.0 mg/dL that appears “normal” but actually corresponds to a CrCl of 30–40 mL/min due to low muscle mass (creatinine production is reduced, giving a falsely reassuring serum creatinine level).

⚠️ Always calculate CrCl (Cockcroft-Gault) or eGFR (CKD-EPI) in elderly patients before prescribing cefadroxil. Do NOT rely on serum creatinine alone.

Example: A 78-year-old woman, 50 kg, serum creatinine 0.9 mg/dL → Cockcroft-Gault CrCl = [(140 – 78) × 50 × 0.85] / (72 × 0.9) = 40.7 mL/min — this requires the CrCl 25–50 dosing adjustment (500 mg BD), not the full standard dose.

Risks specific to elderly:

Risk	Relevance to Cefadroxil	Mitigation
Falls	Cefadroxil does NOT cause dizziness, sedation, or postural hypotension at standard doses. Falls risk is not a significant concern.	No specific mitigation needed beyond general elderly fall-prevention measures.
Postural hypotension	Not a cefadroxil side effect.	Not applicable.
Confusion / delirium	Cephalosporin-induced neurotoxicity (confusion, myoclonus, seizures) is a recognised class effect — almost exclusively in severe renal impairment with drug accumulation. Extremely rare with oral cefadroxil at adjusted doses.	Dose adjust for renal function. Monitor for new confusion in elderly patients on cefadroxil with CrCl <25 mL/min.
Renal reserve decline	Primary concern — see above.	Calculate CrCl/eGFR. Dose adjust.
Polypharmacy interactions	Cefadroxil has very few drug interactions (no CYP450 involvement). Risk of polypharmacy interaction is LOW compared to most other drugs. Probenecid (used for gout in some elderly patients) is the main interacting drug.	Check medication list for probenecid. Otherwise, no specific polypharmacy concern.
GI adverse effects	Elderly patients may be more susceptible to antibiotic-associated diarrhoea. C. difficile risk increases with age.	Monitor for diarrhoea. Shortest effective course. Consider probiotics (evidence limited but practice common in India).
Clostridioides difficile infection	Elderly are a high-risk group for CDI (age >65 is a CDI risk factor). Cefadroxil (first-generation cephalosporin) carries lower CDI risk than third-generation cephalosporins and fluoroquinolones, but risk is not zero.	Use shortest effective duration. Monitor for persistent/severe diarrhoea. If CDI suspected → stool C. difficile toxin assay.
QT prolongation	Cefadroxil does NOT prolong the QT interval. No ECG monitoring needed.	Not applicable.

Anticholinergic burden:No anticholinergic burden. Cefadroxil has zero anticholinergic properties. ACB score = 0. No contribution to cumulative anticholinergic burden when combined with other medications.

Beers Criteria / STOPP-START relevance: Cefadroxil is NOT listed in the American Geriatrics Society Beers Criteria (2023) as a potentially inappropriate medication in the elderly. It is not included in STOPP/START criteria (v3, 2023) as a medication to stop or start. This is a reassuring profile — cefadroxil is one of the safer antibiotics for elderly patients.

Monitoring frequency adjustments in elderly:

Parameter	Monitoring in Elderly
Renal function (CrCl/eGFR)	✔ MANDATORY: Check at baseline before starting cefadroxil. If prolonged course (>7 days), recheck at 1 week.
Hepatic function	Not required (cefadroxil is not hepatotoxic or hepatically metabolised).
CBC	Not routinely required for short courses (≤14 days). Consider if prolonged course (>2 weeks) — monitor for rare eosinophilia or cytopenia.
Stool monitoring (for CDI)	Clinical monitoring — watch for ≥3 loose stools/day. Send stool C. difficile toxin if suspected.

Common clinical scenarios in elderly Indian patients:

Scenario	Notes
Elderly diabetic with recurrent SSTI	Very common in India. Cefadroxil BD is a practical choice for MSSA SSTI. Optimise glycaemic control alongside antibiotics. Screen for MRSA if recurrent.
Elderly patient with CKD on polypharmacy	Calculate CrCl carefully. Cefadroxil has very few drug interactions — a pharmacological advantage in polypharmacy. Adjust dose for CrCl.
Elderly patient with prosthetic valve needing dental procedure	IE prophylaxis: cefadroxil 2 g single oral dose 30–60 minutes before procedure. Adjust for renal function only if CrCl <25 mL/min (single-dose prophylaxis — accumulation risk is minimal with a single dose).
Elderly patient with UTI	Obtain urine culture. Cefadroxil BD is a reasonable directed-therapy option. In elderly Indian patients, always consider enterococcal UTI (cefadroxil has NO enterococcal activity → use amoxicillin/ampicillin if Enterococcus identified).

Deprescribing guidance: Not applicable. Cefadroxil is used as a short-course antibiotic, not as a chronic/long-term medication. No deprescribing considerations.

MAJOR DRUG INTERACTIONS

ℹ️ Cefadroxil has remarkably few clinically significant drug interactions. This is one of its pharmacological strengths, shared with cephalexin. The reasons:

No CYP450 metabolism → no CYP-mediated interactions
Low protein binding (~20%) → no protein displacement interactions
No significant P-gp, OATP, BCRP, OCT2, or MATE involvement at therapeutic concentrations
Renal elimination via glomerular filtration + tubular secretion (OAT1/OAT3)

The only interactions that approach “major” classification involve interference with drug elimination or laboratory tests — NOT life-threatening pharmacodynamic interactions.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Probenecid	Blocks renal tubular secretion of cefadroxil via OAT1/OAT3 inhibition. Also inhibits renal tubular secretion in the proximal tubule.	↑ Cefadroxil serum levels by ~30–50%. Prolonged half-life. Higher Cmax and AUC.	Acute onset (within hours of co-administration)	⚠️ Usually intentional — probenecid was historically co-prescribed to boost cephalosporin levels. In current practice, this interaction is relevant if probenecid is being used for gout and the patient requires cefadroxil for an infection. Action: Monitor for increased cefadroxil adverse effects (GI upset, diarrhoea). Dose reduction of cefadroxil is NOT routinely required unless CrCl is also impaired (double reason for accumulation — probenecid + renal impairment → consider reducing cefadroxil dose by 50% or extending interval).
Methotrexate (high-dose — oncology use)	Cefadroxil may compete with methotrexate for renal tubular secretion (via OAT transporters).	Theoretically ↑ methotrexate levels → increased methotrexate toxicity (mucositis, myelosuppression, nephrotoxicity).	Gradual onset (over 24–72 hours of co-administration)	⚠️ Avoid co-administration with high-dose methotrexate (oncology regimens, e.g., >500 mg/m²). If an antibiotic is needed during high-dose methotrexate therapy, choose one that does not interfere with methotrexate clearance (e.g., azithromycin, meropenem — discuss with oncology). Low-dose methotrexate (e.g., 7.5–25 mg/week for RA/psoriasis) is a lower risk scenario, but monitor methotrexate levels and renal function if co-prescribed.
Warfarin	Mechanism unclear — some cephalosporins may reduce vitamin K-producing gut flora, theoretically potentiating warfarin. Additionally, any acute infection/inflammation can alter warfarin metabolism.	Possible ↑ INR with concurrent cefadroxil + warfarin. Clinical significance is uncertain — case reports exist for some cephalosporins but specific cefadroxil data is limited.	Gradual onset (over 3–7 days)	⚠️ Monitor INR more frequently (every 2–3 days) during the cefadroxil course and for 1 week after completion in patients on warfarin. Adjust warfarin dose if INR rises above target range. This applies to ALL cephalosporins as a class caution. ℹ️ Indian context: many elderly patients on warfarin for RHD with prosthetic valves — always check INR when adding any antibiotic.

Food-Drug Interactions:

Food/Substance	Mechanism	Clinical Effect	Action Required
Food (general)	Delays Tmax slightly, marginal ↓ Cmax. AUC unchanged.	No clinically significant effect on efficacy.	✔ Take with or without food. Taking with food may reduce GI upset. No food restriction.
Dairy products / Calcium	No significant interaction. Unlike fluoroquinolones and tetracyclines, cefadroxil does NOT chelate with divalent cations (Ca²⁺, Mg²⁺, Fe²⁺, Al³⁺).	No effect on absorption.	✔ May be taken with milk or dairy products. This is a practical advantage over doxycycline and fluoroquinolones.
Alcohol	No direct pharmacological interaction. Cefadroxil does NOT have a disulfiram-like reaction (this reaction occurs with specific cephalosporins that have an N-methylthiotetrazole [NMTT] side chain — cefoperazone, cefamandole, cefotetan, moxalactam). Cefadroxil does NOT contain an NMTT side chain.	No disulfiram reaction. However, alcohol should generally be avoided during acute infections (immunosuppressive, dehydrating).	ℹ️ Counsel patients that alcohol is best avoided during an infection course — but this is a general health recommendation, not a specific drug interaction.

Herb-Drug Interactions (India-specific):

Herb/Traditional Medicine	Interaction	Action Required
St. John’s Wort (Hypericum perforatum)	No known interaction with cefadroxil. St. John’s Wort induces CYP3A4, CYP2C9, CYP1A2, and P-gp — but cefadroxil is not a substrate of any CYP enzymes or P-gp.	No action needed.
Ashwagandha (Withania somnifera)	No documented interaction.	No action needed.
Triphala / Giloy (Tinospora cordifolia) / Arjuna (Terminalia arjuna) / Turmeric-curcumin supplements	No documented pharmacokinetic interaction with cefadroxil.	No specific contraindication. General advice: patients should inform their doctor about all traditional/herbal medicines they are taking.

MODERATE DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Aminoglycosides (Gentamicin, Amikacin) — typically co-administered parenterally, but clinically relevant if cefadroxil is the oral component in a mixed regimen	Additive nephrotoxicity. Both drug classes are renally eliminated. Aminoglycosides are directly nephrotoxic.	↑ Risk of nephrotoxicity → subsequent cefadroxil accumulation due to declining renal function.	Gradual onset (over days)	Monitor renal function (serum creatinine, CrCl/eGFR) every 48–72 hours when both drugs are being used. Adjust cefadroxil dose if renal function declines. ℹ️ This scenario is uncommon because cefadroxil is oral-only and aminoglycosides are parenteral — they are rarely co-prescribed in the same regimen. However, it may occur during IV-to-oral transition if the aminoglycoside course overlaps with oral cefadroxil initiation.
Loop diuretics (Furosemide, Torsemide)	Theoretical additive nephrotoxicity (some historical references cite increased cephalosporin nephrotoxicity with high-dose loop diuretics — evidence is weak and based on older cephalosporins). More relevantly: loop diuretics can cause prerenal azotaemia → reduced cefadroxil clearance.	Theoretical ↑ cefadroxil levels if diuretic-induced renal impairment occurs.	Gradual	Monitor renal function, especially in elderly patients on chronic furosemide + cefadroxil. Ensure adequate hydration. Adjust cefadroxil dose if CrCl declines.
NSAIDs (chronic use — Diclofenac, Ibuprofen, Naproxen)	NSAIDs can reduce GFR (afferent arteriole vasoconstriction via prostaglandin inhibition) → reduced cefadroxil clearance. NSAIDs may also compete for OAT-mediated tubular secretion.	Possible ↑ cefadroxil levels with chronic NSAID use. Clinically significant only in patients with pre-existing renal impairment or elderly patients.	Gradual	Monitor renal function in patients on chronic NSAIDs + cefadroxil, especially elderly. Short-course NSAID use (e.g., 3–5 days for acute pain) is unlikely to be significant.
Oral contraceptive pills (OCPs)	Historical concern (widespread belief) that antibiotics reduce OCP efficacy by disrupting enterohepatic recycling of ethinyl estradiol.	Current evidence: cefadroxil (and cephalosporins in general) do NOT significantly reduce OCP efficacy. The only antibiotic with strong evidence for reducing OCP efficacy is rifampicin (potent CYP3A4 inducer).	Not applicable	ℹ️ No additional contraception needed during a cefadroxil course. However, if the patient is concerned, advise barrier contraception during the antibiotic course and for 7 days after as a precautionary measure (this is a conservative recommendation adopted by some Indian practitioners based on older guidance). Dose adjustment of OCP: Not required.
Cholestyramine / Colestipol (bile acid sequestrants)	Bile acid sequestrants can bind to orally administered drugs in the GI tract → ↓ absorption.	Theoretically ↓ cefadroxil absorption if taken simultaneously.	Acute onset	Separate dosing by at least 2 hours: take cefadroxil ≥1 hour before or ≥2 hours after cholestyramine/colestipol. ℹ️ This is a general precaution for all oral medications with bile acid sequestrants, not specific to cefadroxil.
Live vaccines (oral typhoid vaccine — Ty21a, oral polio vaccine — OPV)	Antibiotics may reduce the viability of live oral vaccines by killing or inhibiting the vaccine organism.	Theoretically ↓ immune response to live oral vaccines taken concurrently with cefadroxil. Injectable live vaccines (e.g., MMR, varicella) are NOT affected.	Acute onset	⚠️ Delay live oral vaccine administration until ≥3 days (preferably 7 days) after completing the cefadroxil course. If a live oral vaccine has already been given, wait ≥3 days before starting cefadroxil (if clinically feasible). ℹ️ Indian context: OPV and oral typhoid vaccine are commonly administered — this interaction is practically relevant in paediatric immunisation schedules.
Antacids (Aluminium/Magnesium hydroxide — Gelusil, Digene)	Minimal interaction. Unlike fluoroquinolones and tetracyclines, cefadroxil is NOT chelated by divalent/trivalent cations to a clinically significant degree.	Negligible effect on cefadroxil absorption.	—	No specific action needed. May take concurrently. ℹ️ This is a practical advantage of cefadroxil over ciprofloxacin and doxycycline in Indian patients who frequently self-medicate with antacids.

Laboratory Test Interactions (Drug-Lab interactions):

Test	Interaction	Clinical Significance	Action Required
Urine glucose (copper-reduction methods)	False-positive with Benedict’s reagent, Clinitest, Fehling’s solution.	Diabetic patients may get falsely elevated urine glucose readings.	Use glucose oxidase-based methods (Diastix, glucometer strips) instead. ℹ️ In India, most modern labs and glucometers use glucose oxidase methods — this is primarily relevant in settings using older copper-reduction tests.
Direct Coombs’ test (Direct Antiglobulin Test — DAT)	False-positive DAT. Cephalosporins can cause non-immune adsorption of proteins to the red cell surface → positive DAT without haemolysis.	May confuse transfusion cross-matching and haemolytic anaemia workup.	Inform blood bank / haematology if the patient is on cefadroxil and requires Coombs’ testing or cross-matching. Clinically significant immune haemolytic anaemia from cefadroxil is extremely rare.
Serum/urine creatinine (Jaffe method)	Some cephalosporins (primarily cefoxitin, cefaclor) can cause false elevations in serum creatinine measured by the Jaffe (alkaline picrate) method. Cefadroxil’s interference with the Jaffe method is minimal/not clinically significant.	Unlikely to be clinically relevant for cefadroxil.	No specific action needed. If unexplained creatinine elevation occurs during cefadroxil therapy, consider enzymatic creatinine measurement for confirmation.
Urine protein (certain dip-stick methods)	False-positive proteinuria has been reported rarely with some cephalosporins. Data for cefadroxil is limited.	May cause unnecessary alarm or workup in UTI patients.	If persistent proteinuria is detected on dipstick during cefadroxil therapy, confirm with quantitative protein measurement (24-hour urine protein or urine protein-creatinine ratio).

COMMON ADVERSE EFFECTS

ℹ️ Cefadroxil is very well tolerated. The adverse effect profile is essentially identical to cephalexin. Most adverse effects are mild, dose-related, and reversible upon discontinuation.

Very Common (≥10%):

Adverse Effect	Details
None	No adverse effect occurs in ≥10% of patients receiving cefadroxil at standard doses.

Common (1–10%):

System	Adverse Effect	Approximate Incidence	Notes
Gastrointestinal	Diarrhoea	~3–6%	Most common ADR. Usually mild, self-limited. Due to disruption of normal gut flora. More frequent with higher doses and longer courses. Dose-dependent: more common at 1 g BD than 500 mg BD. Does NOT usually require drug discontinuation. ⚠️ If diarrhoea is severe (≥6 loose stools/day), bloody, or persists >48 hours after stopping cefadroxil → suspect CDI → send stool for C. difficile toxin assay.
Gastrointestinal	Nausea	~2–4%	Mild, transient. Reduced by taking with food.
Gastrointestinal	Abdominal discomfort / cramps	~1–3%	Mild. Usually resolves without intervention.
Gastrointestinal	Dyspepsia	~1–2%
Gastrointestinal	Vomiting	~1–2%	More common in children (related to taste/palatability or volume of suspension). If persistent vomiting occurs within 30 minutes of dose, re-dose. If >30 minutes after dose, do NOT re-dose.
Dermatological	Skin rash (maculopapular, non-urticarial)	~1–3%	Usually mild, not requiring discontinuation. If rash is generalised, pruritic, or progressive → discontinue and evaluate for allergy. Differentiate from viral exanthem (especially in children with pharyngitis — rash may be from the underlying infection, not the drug).
Genital / Mucosal	Vaginal candidiasis / Vulvovaginal pruritus	~1–3% (in women)	Due to disruption of vaginal flora. More common with prolonged courses (>7 days). Treat with topical clotrimazole or single-dose oral fluconazole 150 mg.
Genital / Mucosal	Oral candidiasis (thrush)	~1–2%	White patches on tongue/buccal mucosa. More common in immunocompromised patients and infants. Treat with oral nystatin suspension.

SERIOUS ADVERSE EFFECTS

ℹ️ Serious adverse effects of cefadroxil are rare. The serious ADR profile is a class effect of cephalosporins and beta-lactam antibiotics — NOT unique to cefadroxil.

Adverse Effect	Approximate Frequency	Details	Action Required
Anaphylaxis / Severe hypersensitivity reaction	<1 in 10,000 (very rare)	Type I hypersensitivity: urticaria → angioedema → bronchospasm → cardiovascular collapse. Can occur with first dose or with re-exposure in a previously sensitised patient. May occur within minutes to 1 hour after dose.	⛔ STOP cefadroxil immediately. Treat per anaphylaxis protocol: IM adrenaline (epinephrine) 0.3–0.5 mg (1:1000) mid-anterolateral thigh (adult); 0.01 mg/kg in children (max 0.3 mg). IV fluids, oxygen, antihistamines, corticosteroids. Antidote/reversal: IM adrenaline (epinephrine) — available at all levels of healthcare in India (included in NLEM). Transfer to hospital. ⚠️ Report to nearest ADR Monitoring Centre under PvPI.
Clostridioides difficile-associated diarrhoea (CDAD) / Pseudomembranous colitis	<1% (uncommon, but higher in elderly and hospitalised patients)	Profuse watery or bloody diarrhoea, abdominal pain, fever, leukocytosis. Can occur during therapy or up to 8 weeks after completing the course. More common with broad-spectrum cephalosporins (third-gen) and fluoroquinolones, but can occur with first-gen cephalosporins.	⛔ STOP cefadroxil. Send stool for C. difficile toxin assay (GDH + Toxin A/B ELISA or NAAT). Treat confirmed CDI with oral vancomycin 125 mg QDS × 10 days (first-line) or oral fidaxomicin (if available). Metronidazole 400 mg TDS × 10 days is an alternative in non-severe CDI. ⛔ Do NOT use loperamide/anti-motility agents. ⚠️ Report to PvPI.
Serum sickness-like reaction (SSLR)	<1 in 10,000 (very rare; more commonly reported in children with cefaclor — less common with cefadroxil)	Fever, arthralgia, rash (urticarial or maculopapular), lymphadenopathy, appearing 7–21 days after starting therapy. Not a true immune complex disease — mechanism is unclear.	Stop cefadroxil. Treat with antihistamines and oral corticosteroids (prednisolone 1 mg/kg/day × 3–5 days) if symptoms are significant. Resolves spontaneously within 1–2 weeks of drug discontinuation. Avoid re-challenge with cefadroxil. ⚠️ Report to PvPI.
Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	<1 in 100,000 (extremely rare)	Severe mucocutaneous reaction: painful skin with targetoid lesions, blistering, mucosal involvement (oral, conjunctival, genital), epidermal detachment. SJS: <10% BSA detachment. TEN: >30% BSA detachment. Life-threatening (TEN mortality 25–35%).	⛔ STOP cefadroxil immediately. Do NOT re-challenge. EVER. Emergency dermatology/burns unit referral. Supportive care (IV fluids, wound care, pain management). IVIG and/or ciclosporin may be used (specialist decision). ⚠️ Report to PvPI.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)	<1 in 100,000 (extremely rare)	Fever, diffuse maculopapular rash, facial oedema, lymphadenopathy, eosinophilia (>1500/mm³), hepatitis (↑ ALT/AST), sometimes nephritis, pneumonitis. Onset typically 2–8 weeks after starting drug.	⛔ STOP cefadroxil. Check CBC with differential (eosinophilia), LFT (hepatitis), renal function. Systemic corticosteroids (prednisolone 1 mg/kg/day, tapered over 8–12 weeks). Dermatology and allergy referral. ⚠️ Report to PvPI.
Haemolytic anaemia (drug-induced immune haemolytic anaemia — DIIHA)	<1 in 100,000 (extremely rare)	Coombs-positive haemolytic anaemia. Presents with fatigue, pallor, jaundice, dark urine, ↑ LDH, ↓ haptoglobin, ↑ reticulocyte count, positive DAT.	⛔ Stop cefadroxil. Supportive care. Transfusion if severe (notify blood bank of drug-induced Coombs positivity). Most cases resolve within days to weeks after drug discontinuation. ⚠️ Report to PvPI.
Interstitial nephritis (acute — drug-induced AIN)	<1 in 100,000 (extremely rare; reported with various cephalosporins)	Fever, rash, eosinophilia, rising creatinine, eosinophiluria. Onset days to weeks after starting therapy.	⛔ Stop cefadroxil. Nephrology referral. Renal biopsy if diagnosis uncertain. Corticosteroids may hasten recovery (specialist decision). Most cases resolve after drug discontinuation. ⚠️ Report to PvPI.
Seizures / Neurotoxicity	Extremely rare with oral cefadroxil at therapeutic doses. Reported primarily with parenteral cephalosporins at high doses in renal failure.	Myoclonus, confusion, encephalopathy, generalised tonic-clonic seizures. Risk factors: renal impairment (drug accumulation), pre-existing seizure disorder, very high doses.	⛔ Stop cefadroxil. Treat seizure with IV diazepam 5–10 mg or IV lorazepam 2–4 mg. Address renal impairment (dose adjustment was likely inadequate). Drug levels (if available) to confirm accumulation. ⚠️ Report to PvPI.
Agranulocytosis / Severe neutropenia	<1 in 100,000 (extremely rare; class effect of cephalosporins, typically with prolonged courses >2 weeks)	ANC <500/mm³. Presents with fever, sore throat, infection.	⛔ Stop cefadroxil. Obtain CBC immediately. Neutropenic precautions. G-CSF if severe. Usually reversible within 5–10 days of drug discontinuation. ⚠️ Report to PvPI.
Thrombocytopenia (drug-induced immune thrombocytopenia)	<1 in 100,000 (extremely rare)	↓ Platelets. Presents with petechiae, purpura, mucosal bleeding.	⛔ Stop cefadroxil. Monitor platelet count. Usually resolves within 1–2 weeks. ⚠️ Report to PvPI.

⚠️ PvPI reporting reminder: For ALL serious adverse effects listed above: Report to the nearest ADR Monitoring Centre under the Pharmacovigilance Programme of India (PvPI) or via the ADR reporting form on the CDSCO website (www.cdsco.gov.in) or via the ADR reporting app.

Black Box equivalent warnings: There are NO CDSCO black box equivalent warnings for cefadroxil. No REMS or risk evaluation/mitigation strategy applies.

MONITORING REQUIREMENTS

ℹ️ Cefadroxil requires minimal monitoring for most clinical scenarios. This is a significant practical advantage — particularly in Indian primary care and PHC settings where laboratory access may be limited.

Baseline (Before Starting):

Parameter	Priority Level	Details
Renal function (serum creatinine, eGFR/CrCl)	RECOMMENDED (MANDATORY in: elderly ≥60 years, known CKD, diabetes, dehydration, concurrent nephrotoxic drugs)	Cefadroxil is renally eliminated. Dose adjustment required if CrCl <50 mL/min. In healthy young adults with no risk factors for renal impairment, renal function testing can be deferred for short courses (5–7 days) of standard doses.
Allergy history	MANDATORY	Ask specifically about: (a) prior reaction to ANY cephalosporin, (b) prior reaction to ANY penicillin (including amoxicillin, ampicillin — shared side chain with cefadroxil), © nature of the reaction (rash vs anaphylaxis — critically different implications). Document the response in the medical record.
Infection-specific cultures	RECOMMENDED (MANDATORY for: UTI, wound/abscess, treatment failure, serious infections)	Urine C/S for UTI. Wound swab C/S for SSTI. Throat culture / RADT for pharyngitis (if available). Blood cultures for bacteraemia/serious infections. Obtain BEFORE starting empiric therapy.
CBC	OPTIONAL but helpful	Baseline CBC not mandatory for short courses. Useful for: baseline WBC in SSTI/UTI (to monitor response), ruling out other diagnoses (e.g., mononucleosis in pharyngitis — atypical lymphocytes).
Hepatic function (LFT)	NOT required	Cefadroxil is not hepatotoxic or hepatically metabolised. No baseline LFT needed. Exception: if there is clinical suspicion of liver disease for other reasons.
Blood glucose / HbA1c	OPTIONAL	Not for cefadroxil monitoring — but clinically relevant to screen for diabetes in recurrent SSTI (common Indian scenario).
Pregnancy test	NOT required	Cefadroxil is pregnancy-safe. No pregnancy testing mandate.

Resource-limited setting (PHC/CHC) guidance: In settings where serum creatinine is unavailable, use clinical surrogates for renal function assessment: (a) age >60 years, (b) history of kidney disease, © poorly controlled diabetes, (d) chronic NSAID use, (e) recent dehydration → if ANY of these are present, attempt to obtain serum creatinine before prescribing, or use reduced dosing empirically (500 mg BD for mild-moderate infections) until renal function can be confirmed.

After Initiation / During Treatment:

Parameter	When to Check	Details
Clinical response assessment	48–72 hours after starting therapy	✔ MANDATORY for all patients. Assess: Is the infection improving? Symptoms resolving? Fever breaking? Erythema regressing? For SSTI: mark cellulitis borders at day 0 and compare at day 2–3. For UTI: are dysuria/frequency improving? For pharyngitis: is throat pain improving?
Renal function (if impaired at baseline or patient at risk)	Day 5–7 for courses >7 days	RECOMMENDED in elderly, CKD, diabetics, dehydrated patients, or concurrent nephrotoxic drug use.
Stool monitoring (for C. difficile)	Throughout treatment and up to 8 weeks after	Clinical monitoring: watch for ≥3 loose stools/day, bloody diarrhoea, abdominal pain with fever. Send stool C. difficile toxin if suspected.
Culture results review	When available (usually 48–72 hours)	Review sensitivity report and narrow/adjust therapy accordingly. If organism is resistant to cefadroxil → switch to susceptible agent.
INR (if on warfarin)	Day 3–5 of concurrent therapy	RECOMMENDED for patients on warfarin. Recheck INR 3–5 days after starting cefadroxil and 5–7 days after completing the course.

Long-Term / Maintenance Monitoring (For Prolonged Courses >14 Days or Prophylactic Use):

Parameter	Frequency	Details
CBC with differential	Every 2–4 weeks during prolonged therapy	Monitor for rare eosinophilia, neutropenia, thrombocytopenia. If neutropenia develops (ANC <1500/mm³), reassess need for continued therapy.
Renal function	Every 2–4 weeks during prolonged therapy	Especially in elderly and CKD patients.
LFT	Every 4 weeks if course exceeds 4 weeks	Although cefadroxil is not hepatotoxic, prolonged cephalosporin courses can rarely cause transient transaminase elevations. Primarily precautionary.
Clinical assessment for superinfection	At each follow-up visit	Oral thrush, vaginal candidiasis, persistent diarrhoea.
Urine culture (for UTI prophylaxis)	Periodic (every 3 months during prophylaxis)	To monitor for breakthrough UTI and emerging resistance.

Therapeutic Drug Monitoring (TDM):

Not applicable. Cefadroxil does NOT require therapeutic drug monitoring. It has a wide therapeutic index, and routine TDM is not available or necessary. There are no target trough or peak levels defined for clinical use.

When to Stop Monitoring:

For short courses (5–10 days): No ongoing monitoring needed after course completion unless adverse effects developed.
For prophylactic use (recurrent UTI): Monitor as above until prophylaxis is discontinued (specialist decision).
Post-treatment: No long-term monitoring required after completing a cefadroxil course.

PATIENT COUNSELLING

ℹ️ Written in simple language that a doctor can directly convey to the patient during consultation. This is NOT for unsupervised patient self-management — it is a ready reference for the prescribing clinician to use during patient education.

What this medicine is for:

“This is an antibiotic — a medicine that kills bacteria causing your infection. It works against common skin infections, throat infections, and urine infections. It does NOT work against viral infections like the common cold or flu.”

How to take it:

“Take this medicine twice a day — once in the morning and once in the evening — about 12 hours apart. For example, 8 AM and 8 PM.”
“For throat infection (strep throat), your doctor may prescribe it once a day — take it at the same time every day.”
“You can take it with food or without food — whichever you prefer. Taking it with a meal may reduce stomach upset.”
“Swallow capsules and tablets whole with a full glass of water. Do NOT crush, chew, or open capsules.”
“For liquid medicine (syrup/suspension): Shake the bottle well before every dose. Use the measuring cup or syringe provided — do NOT use a household spoon, as it may give the wrong amount.”
“After mixing the powder to make the liquid medicine, store it in the fridge and use it within 14 days. Write the date you mixed it on the bottle. Throw away any leftover medicine after 14 days.”

What to do if you miss a dose:

“If you take it twice a day and forget a dose: Take it as soon as you remember, but only if there are more than 6 hours until your next dose. If less than 6 hours remain, skip the missed dose and take the next one at the regular time.”
“If you take it once a day (for throat infection) and forget: Take it as soon as you remember, but only if there are more than 12 hours until your next dose. If less than 12 hours remain, skip the missed dose and take the next one tomorrow at the regular time.”
“Never take two doses at once to make up for a missed dose.”
“If you miss a day during a throat infection course, add one extra day at the end to make up the full 10 days.”

Common side effects to expect:

“You may experience mild loose stools or diarrhoea — this is the most common side effect. It happens because the medicine affects some of the normal healthy bacteria in your gut. It usually settles on its own. Drink plenty of fluids.”
“You may feel mild nausea or stomach discomfort — taking the medicine with food usually helps.”
“Women may develop vaginal itching or a white discharge (yeast infection) during or after the course. This is treatable — inform your doctor.”
“Babies and young children may develop white patches in the mouth (oral thrush) or a diaper rash. Inform your doctor.”

Warning signs — report to your doctor immediately:

“⚠️ Severe diarrhoea (more than 5–6 loose stools a day), especially if it is watery, bloody, or has mucus — this could be a serious bowel infection caused by the antibiotic.”
“⚠️ Skin rash, hives (raised itchy bumps), swelling of the face/lips/tongue, or difficulty breathing — this could be a serious allergic reaction. Go to the nearest hospital immediately.”
“⚠️ Yellow eyes or skin, very dark urine, severe abdominal pain — these could be signs of a rare liver or blood problem.”
“⚠️ Fever, severe sore throat, or mouth ulcers developing during the antibiotic course — these could rarely be a sign of a blood cell problem.”
“⚠️ If your infection is not improving after 3 days of taking the medicine — contact your doctor. The medicine may need to be changed.”

Things to avoid:

“There is no strict food restriction with this medicine. You can eat normally. You can drink milk and dairy products.”
“Alcohol: It is best to avoid alcohol while you are fighting an infection. This medicine does not cause a dangerous reaction with alcohol (unlike some other antibiotics), but alcohol can slow your recovery.”
“This medicine does NOT cause drowsiness — you can drive and operate machinery normally.”
“Do NOT take any other antibiotic at the same time without your doctor’s advice.”

Storage:

“Store capsules and tablets in a cool, dry place — below 30°C. Keep them in the original packaging. Protect from moisture.”
“In hot weather (Indian summer), avoid storing medicines near windows, in cars, or in direct sunlight. A cupboard away from the kitchen stove is ideal.”
“Liquid medicine (after mixing): Keep in the refrigerator (2–8°C). Use within 14 days. If you do not have a refrigerator, keep it in the coolest part of the house and use within 7 days.”
“Keep all medicines out of reach of children.”

Duration — importance of completing the full course:

“Take this medicine for the full number of days prescribed by your doctor — even if you feel completely better before the course is finished.”
“For throat infection (strep throat): You MUST complete all 10 days. Stopping early — even if your throat feels better after 2 days — can allow the bacteria to survive and cause a serious heart disease called rheumatic fever. This is especially important in India.”
“For skin infection: Complete the full 5–7 days (or as prescribed).”
“For urine infection: Complete the full 5–7 days (or as prescribed). Symptoms may improve within 1–2 days, but the bacteria may not be fully cleared.”
“Do NOT stop early. Do NOT save leftover antibiotics for later use. Do NOT share your antibiotics with anyone else.”

Follow-up:

“Return to your doctor if symptoms are not improving after 3 days.”
“Return immediately if symptoms are getting worse at any point.”
“For throat infection: No routine follow-up throat culture is needed if symptoms resolve. Return if symptoms recur within 2–4 weeks.”
“For urine infection: Your doctor may request a repeat urine test after completing the course to confirm the infection is cleared — this is especially important in pregnant women, children, and patients with recurrent UTIs.”

Common patient questions addressed:

Question	Answer
“Can I take this with my other medicines?”	“This medicine has very few interactions with other medicines. However, always tell your doctor about ALL medicines you are taking — including medicines for gout (probenecid), blood thinners (warfarin), or any herbal/Ayurvedic preparations.”
“Can I take this during fasting (Ramadan/Navratri/Ekadashi)?”	“If you are taking it twice a day: Take one dose at the pre-dawn meal (suhoor/sehri) and one at the evening meal (iftar/breaking fast). The 12-hour interval is maintained. If you are taking it once a day (for throat infection): Take it with your evening meal. Do NOT skip doses during fasting. The antibiotic course must be completed fully — your health takes priority.”
“Will this affect my ability to drive or work?”	“No. This medicine does not cause drowsiness, dizziness, or impaired concentration at normal doses.”
“Is this medicine habit-forming?”	“No. This is an antibiotic, not a habit-forming medicine. It does not cause dependence or addiction. You will stop taking it after the prescribed course is finished.”
“Can I stop once I feel better?”	“No — you must complete the full course. Feeling better means the medicine is working, but bacteria may still be alive. Stopping early allows resistant bacteria to survive and the infection may come back — and may be harder to treat the second time.”
“Is this the same as cephalexin?”	“It is very similar. Both belong to the same family of antibiotics and work against the same bacteria. The main difference is that cefadroxil needs to be taken only twice a day (or even once a day for throat infection), while cephalexin is usually taken three or four times a day. Your doctor chose this one because the simpler dosing schedule may be easier for you to follow.”
“My child’s urine test showed bacteria but she has no symptoms — does she still need antibiotics?”	“This depends on the clinical situation. In some cases (especially pregnant women), bacteria in urine without symptoms DO need treatment. In children, your doctor will decide based on the specific situation. Always follow your doctor’s advice.”
“The liquid medicine tastes bad — my child refuses to take it.”	“Try mixing the measured dose with a small amount of juice, flavoured milk, or yoghurt — give it immediately after mixing. Some children accept it better when given cold (from the fridge). If the child still refuses, ask your doctor if a different brand with a different flavour is available. Do NOT reduce the dose to make it more acceptable — always give the full prescribed amount.”

Caregiver/Family Counselling (for paediatric patients, elderly with cognitive impairment):

“Counsel the caregiver/family member on:”

Dose preparation: “Shake the bottle well. Use the measuring device provided. DO NOT use a household spoon.”
Timing: “Give doses at the same times every day. Set a phone alarm as a reminder.”
Storage: “Keep the liquid medicine in the fridge. Mark the date you mixed it. Throw it away after 14 days.”
Monitoring: “Watch for diarrhoea (especially in babies — it can cause dehydration quickly), rash, vomiting, or refusal to eat/drink.”
When to return: “Bring the child back if: (a) fever is not coming down after 2–3 days, (b) the child is vomiting every dose and cannot keep the medicine down, © the child develops a rash, (d) diarrhoea becomes severe or bloody, (e) the child seems more unwell than before.”
Course completion: “Complete ALL 10 days for throat infection. Do NOT stop early even if the child seems well.”
For elderly patients on polypharmacy: “If the patient is taking many medicines, use a pill box or daily medicine tray. Cefadroxil is only twice a day — label the box clearly (MORNING + EVENING).”

India-specific adherence support:

Concern	Guidance
Cost-driven non-adherence	“If cost is a concern, ask your doctor about Jan Aushadhi (government pharmacy) alternatives. Cefadroxil is available at significantly lower prices at Jan Aushadhi stores. The generic medicine works the same as branded versions.”
Polypharmacy burden	“If you are taking many medicines, ask your doctor to review which ones are essential. Cefadroxil is a short-term antibiotic course — it will be stopped after 5–10 days.”
Temperature-sensitive storage (hot climate)	“In summer, if your area frequently exceeds 35°C, store liquid medicines in the fridge or the coolest part of the house. Do NOT leave medicines in a car, near a window, or in direct sunlight. Capsules and tablets can be stored at room temperature but should be kept dry — avoid storing in the bathroom.”
Rural access / refill difficulty	“If you cannot get a refill on time (e.g., pharmacy is far away), ask your doctor to prescribe the full course quantity at the first visit. For a 10-day throat infection course, you will need 10 tablets (once-daily regimen) or 20 capsules (twice-daily regimen) — ensure you receive the full quantity at the pharmacy.”
Stigma	Not applicable — antibiotic use does not carry social stigma.

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands:

ℹ️ Cefadroxil is listed in the Jan Aushadhi (PMBJP) product catalogue. Availability at individual Jan Aushadhi stores may vary — check with the nearest PMBJP outlet or the PMBJP online portal (janaushadhi.gov.in).

Brand Name	Manufacturer	Formulation	Strength	Availability Note
Jan Aushadhi Cefadroxil	PMBJP (Bureau of Pharma PSUs of India — BPPI) contracted manufacturer	Capsules	500 mg	Available at Jan Aushadhi Kendras. Verify stock at local centre.
Jan Aushadhi Cefadroxil	PMBJP	Dry syrup	125 mg/5 mL	Limited availability — not all stores stock paediatric formulations.

Major Private Brands (commonly prescribed / widely available):

Brand Name	Manufacturer	Formulation(s)	Strength(s)	Availability Note
Droxyl	Cipla Ltd	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL dry syrup	Widely available — one of the most commonly prescribed cefadroxil brands in India.
Odoxil	Sun Pharma / Sun Pharmaceutical Industries Ltd	Capsules; Tablets; Dry syrup	500 mg caps; 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL dry syrup	Widely available. 500 mg/5 mL concentration available (convenient for older children).
Cefadur	Aristo Pharmaceuticals	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL dry syrup	Widely available.
Adocef	Micro Labs Ltd	Capsules; Dry syrup; Dispersible tablets	500 mg caps; 125 mg/5 mL, 250 mg/5 mL dry syrup; 250 mg DT	Widely available. Dispersible tablet option useful for paediatric patients.
Roxil	Alkem Laboratories	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL dry syrup	Widely available.
Cefadrox	Ranbaxy (now Sun Pharma)	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL dry syrup	Widely available.
Velocef	Dr. Reddy’s Laboratories (select markets)	Capsules	500 mg	Major metros primarily. Limited rural availability.
Kefloxin	Torrent Pharmaceuticals	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL	Widely available.
Bidocef	Mankind Pharma	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL	Widely available. Mankind’s extensive rural distribution network makes this brand accessible in smaller towns.
Cefadin	Zydus Cadila (Zydus Lifesciences)	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL dry syrup	Widely available.
Cedomax	Macleods Pharmaceuticals	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL	Widely available.
Starcef	Lupin Ltd	Capsules; Dry syrup	500 mg caps; 125 mg/5 mL, 250 mg/5 mL	Widely available.

ℹ️ 1 g tablet availability: The 1 g (1000 mg) tablet/capsule strength — useful for single-tablet OD dosing in GAS pharyngitis (1 g OD × 10 days) and for high-dose BD therapy — is available from select manufacturers (Odoxil 1 g tablet — Sun Pharma; limited other brands). Availability may be restricted to major metros and hospital pharmacies. If 1 g tablets are unavailable, prescribe two 500 mg capsules as a single dose.

ℹ️ Paediatric drops (100 mg/mL): Available from limited manufacturers. Check local availability. If unavailable, use the dry syrup formulation with accurate volume measurement.

FDC Brands (limited clinical relevance):

FDC	Brand Example	Manufacturer	Notes
Cefadroxil 500 mg + Clavulanic acid 125 mg	Select brands from smaller manufacturers	Various	⚠️ NOT widely recommended. See Formulations section for rationale. Amoxicillin-clavulanate is preferred when a BL/BLI combination is needed.

CDSCO Not of Standard Quality (NSQ) Alerts:

ℹ️ Prescribers should periodically check the CDSCO website (www.cdsco.gov.in → “Alerts” section) for the latest list of Not of Standard Quality (NSQ) drug batches. NSQ alerts are batch-specific, not brand-wide — a single NSQ alert does not necessarily indicate a systemic quality problem with the manufacturer. As of the most recent review (2024), multiple cefadroxil brands from smaller/regional manufacturers have appeared in NSQ alerts for individual batches. The major national brands listed above (Cipla, Sun Pharma, Aristo, Micro Labs, Alkem, Mankind, Zydus, Macleods, Lupin) generally maintain consistent quality, but individual batch issues can occur with any manufacturer.

PRICE RANGE (INR)

⚠️ Prices as of June 2025. Verify current prices on NPPA (nppa.gov.in), 1mg, PharmEasy, or Jan Aushadhi price lists as prices may change.

ℹ️ Cefadroxil is included in NLEM India 2022 and is NPPA price-controlled under the Drug Prices Control Order (DPCO). Ceiling prices are set by NPPA for scheduled formulations.

Per-unit prices (approximate retail range — private pharmacies):

Formulation	Strength	Approximate Price Range (INR per unit)	NPPA Controlled?	Notes
Capsules	500 mg	₹8–18 per capsule	✔ Yes	Wide variation between brands. Jan Aushadhi brands at the lower end. Premium brands at the upper end.
Tablets	1 g (1000 mg)	₹15–30 per tablet	✔ Yes (where scheduled)	Limited manufacturers — price may be slightly higher.
Dry syrup (powder for reconstitution)	125 mg/5 mL (30 mL bottle)	₹35–70 per bottle	✔ Yes
Dry syrup	250 mg/5 mL (30 mL bottle)	₹50–90 per bottle	✔ Yes
Dry syrup	250 mg/5 mL (60 mL bottle)	₹80–140 per bottle	✔ Yes
Dry syrup	500 mg/5 mL (30 mL bottle)	₹70–120 per bottle	✔ Yes	Select manufacturers only.
Dispersible tablets	250 mg	₹6–12 per tablet	✔ Yes (where scheduled)	Limited availability.

Jan Aushadhi / PMBJP prices (approximate):

Formulation	Strength	PMBJP Price (INR — approximate)	Notes
Capsules	500 mg	~₹3–5 per capsule	Significantly cheaper than private brands. Availability varies by store.
Dry syrup	125 mg/5 mL (30 mL)	~₹20–30 per bottle	Check individual store stock.

Per-course cost estimates (common clinical scenarios):

Clinical Scenario	Regimen	Total Quantity Needed	Approximate Cost Range (Private Retail, INR)	Jan Aushadhi Cost (INR, approximate)
GAS pharyngitis — OD regimen (adult)	1 g OD × 10 days	10 × 1 g tablets (or 20 × 500 mg capsules)	₹150–300 (1 g tabs) or ₹160–360 (20 × 500 mg caps)	₹60–100 (500 mg caps)
GAS pharyngitis — BD regimen (adult)	500 mg BD × 10 days	20 × 500 mg capsules	₹160–360	₹60–100
SSTI — standard (adult)	500 mg BD × 7 days	14 × 500 mg capsules	₹112–252	₹42–70
SSTI — high-dose (adult)	1 g BD × 7 days	14 × 1 g tablets (or 28 × 500 mg caps)	₹210–420 (1 g tabs) or ₹224–504 (28 × 500 mg caps)	₹84–140 (500 mg caps)
UTI — cystitis (adult)	500 mg BD × 7 days	14 × 500 mg capsules	₹112–252	₹42–70
Pharyngitis — paediatric (15 kg child, OD)	450 mg (≈9 mL of 250 mg/5 mL) OD × 10 days	~90 mL suspension → 2 × 60 mL bottles of 250 mg/5 mL	₹160–280 (2 bottles)	₹40–60
IE prophylaxis (adult — single dose)	2 g single dose	4 × 500 mg capsules (single occasion)	₹32–72	₹12–20

Cost comparison with cephalexin (same indication — 7-day SSTI, 500 mg regimen):

Drug	Regimen	Total Capsules (7-day course)	Approximate Cost Range (Private, INR)	Jan Aushadhi (INR, approximate)
Cefadroxil	500 mg BD × 7 days	14 capsules	₹112–252	₹42–70
Cephalexin	500 mg TDS × 7 days	21 capsules	₹84–210	₹35–63
Cephalexin	500 mg QDS × 7 days	28 capsules	₹112–280	₹47–84

ℹ️ Cost summary: Cefadroxil per-capsule price is slightly higher than cephalexin, but the total course cost is often comparable or even lower because fewer capsules are needed (14 BD vs 21 TDS or 28 QDS). The cost difference is modest and should NOT be the primary driver of choice between these two drugs — adherence advantage (BD vs TDS/QDS) is more clinically significant.

💡 Government supply / Hospital procurement: In government hospitals and public health facilities, cefadroxil is procured through rate contract tenders at substantially lower prices than private retail. Availability in government supply chains varies by state — some states preferentially stock cephalexin over cefadroxil. Check state drug procurement lists.

CLINICAL PEARLS

💡 Pearl 1: The “one-a-day for ten days” advantage — cefadroxil’s unique niche for GAS pharyngitis. [Evidence-based]

Cefadroxil 1 g OD × 10 days is the simplest evidence-based oral regimen for GAS pharyngitis eradication. Ten pills, one per day, no food restriction. No other oral antibiotic offers this combination of simplicity for a mandatory 10-day course. In India — where rheumatic heart disease burden is the world’s highest and 10-day course completion rates are notoriously poor — this regimen has direct public health relevance. When a prescriber judges that adherence to BD or TDS dosing is unlikely, cefadroxil OD should be strongly considered. [Pichichero et al., 1994; Disney et al., 1992]

💡 Pearl 2: Cefadroxil for SSTI = cephalexin for SSTI, but with half the daily pills. [Practice-based]

For a typical 7-day SSTI course: cefadroxil BD = 14 capsules total; cephalexin TDS = 21; cephalexin QDS = 28; cloxacillin QDS = 28. The efficacy is identical — the same organisms, same MICs, same kill kinetics. The difference is entirely about practical convenience. In Indian outpatient practice, where patients frequently discontinue antibiotics once they “feel better” (typically day 3–4), fewer daily doses may improve completion rates. When choosing between cefadroxil and cephalexin for outpatient SSTI, ask: “Will this patient reliably take 3–4 doses per day for a week?” If the answer is uncertain, choose cefadroxil BD.

💡 Pearl 3: Do NOT use cefadroxil for osteomyelitis oral step-down — cephalexin is the right choice. [Evidence-based]

This is perhaps the most important “when NOT to use cefadroxil” message. Cefadroxil’s maximum daily dose is 2 g (1 g BD). Osteomyelitis oral step-down requires 4 g/day (cephalexin 1 g q6h) to achieve adequate bone tissue levels and maintain fT>MIC throughout the 6-hour dosing interval. Cefadroxil 1 g BD provides fT>MIC for only ~50–60% of the 12-hour interval — pharmacokinetically marginal for serious bone infections. If a patient needs oral first-generation cephalosporin step-down for osteomyelitis, always use cephalexin q6h, not cefadroxil BD. [OVIVA trial context; Indian ID practice consensus]

💡 Pearl 4: Cefadroxil is your friend in the breastfeeding mother with mastitis. [Practice-based]

Infective lactational mastitis (S. aureus — MSSA) requires an anti-staphylococcal antibiotic that is: (a) effective against MSSA, (b) safe for the breastfed infant, © compatible with continued breastfeeding, and (d) easy to take for a mother managing an infant. Cefadroxil ticks all four boxes: excellent MSSA activity, very low milk transfer (RID ~1%), compatible with breastfeeding, and BD dosing (morning and evening — minimal disruption to the feeding/care routine). Cloxacillin QDS on an empty stomach is the theoretical first-line — but in a sleep-deprived breastfeeding mother, QDS empty-stomach dosing is a recipe for non-adherence. Cefadroxil BD with food is the pragmatic choice.

💡 Pearl 5: Myth vs Fact — “Cefadroxil and cephalexin are different-generation drugs with different spectra.”

Myth: “Cefadroxil is a newer/stronger antibiotic than cephalexin” — a misconception occasionally encountered in Indian clinical practice, sometimes leading to inappropriate use of cefadroxil as a “step-up” from cephalexin when treatment fails.

Fact: Cefadroxil and cephalexin are both first-generation cephalosporins with identical spectra. Cefadroxil is NOT newer, stronger, or broader than cephalexin. The ONLY difference is pharmacokinetic — cefadroxil has a longer half-life (~1.5 h vs ~1 h) enabling BD dosing. If a patient fails cephalexin therapy, switching to cefadroxil will NOT provide any additional antimicrobial coverage. Treatment failure with cephalexin requires reassessment of the diagnosis and organism (resistant organism? MRSA? wrong diagnosis?), not substitution with cefadroxil. [Goodman & Gilman, 14th Edition; API Textbook]

💡 Pearl 6: No CYP interactions, no food restrictions, no disulfiram reaction — the “worry-free” antibiotic for polypharmacy patients. [Evidence-based]

Cefadroxil has essentially no clinically significant drug interactions (no CYP450 metabolism, no P-gp interaction, no QT prolongation, no chelation with divalent cations). It can be taken with or without food, with dairy, and does NOT cause a disulfiram-like reaction with alcohol (unlike cefoperazone/cefotetan). For elderly patients on 5–10 medications for hypertension, diabetes, and cardiac disease — where every new drug raises interaction concerns — cefadroxil is one of the safest antibiotics to add temporarily. The only interaction to check is probenecid (used for gout — increasingly uncommon) and warfarin (monitor INR as with any antibiotic). [Goodman & Gilman, 14th Edition; CDSCO product inserts]

VERSION

RxIndia v0.1 — 16 Mar 2026

REFERENCES

The following sources were used to generate this monograph. Citation specificity is provided where applicable.

Indian Regulatory & Formulary Sources:

CDSCO Product Inserts — Cefadroxil monohydrate capsules 500 mg and dry syrup 250 mg/5 mL: Droxyl (Cipla Ltd); Odoxil (Sun Pharmaceutical Industries Ltd); Cefadur (Aristo Pharmaceuticals). Reviewed for: approved indications, dosing, contraindications, adverse effects, drug interactions, pharmacokinetic data. Insert revision dates: 2021–2023 (as available on CDSCO and manufacturer websites).
National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Cefadroxil listed under Section 6 (Anti-infective medicines), Sub-section 6.2 (Antibacterials), Category: First-generation cephalosporins (oral).
National Pharmaceutical Pricing Authority (NPPA) — Drug Prices Control Order (DPCO) ceiling price notifications for cefadroxil formulations. Accessed via nppa.gov.in, 2024–2025.
Indian Pharmacopoeia (IP) 2022 — Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Cefadroxil and Cefadroxil Monohydrate — physicochemical specifications, identification, assay methods.
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — Jan Aushadhi product catalogue. Accessed via janaushadhi.gov.in, 2025. Cefadroxil capsules 500 mg listed.

Indian Clinical Guidelines & Textbooks:

API Textbook of Medicine — Association of Physicians of India. 11th Edition, 2019. Chapters on: Antimicrobial Therapy (rational antibiotic prescribing, first-generation cephalosporin use); Skin and Soft Tissue Infections; Urinary Tract Infections; Upper Respiratory Tract Infections; Infective Endocarditis.
ICMR Treatment Guidelines on Antimicrobial Use in Common Syndromes, 2022 — Indian Council of Medical Research. Sections on: Empiric antibiotic therapy for community-acquired SSTI, UTI, upper respiratory infections. First-generation cephalosporins referenced for MSSA SSTI and culture-directed UTI therapy.
ICMR Annual Report on Antimicrobial Resistance (AMR) Surveillance, 2023 — Indian Council of Medical Research, National AMR Surveillance Network. Community E. coli and K. pneumoniae susceptibility data for first-generation cephalosporins in India.
IAP (Indian Academy of Pediatrics) Guidelines — Guidelines on Management of Acute Pharyngitis and Prevention of Rheumatic Fever (updated 2017); Guidelines on Urinary Tract Infections in Children (2011/2017 update); Guidelines on Acute Otitis Media. IAP Drug Formulary.
AIIMS Antibiotic Policy — All India Institute of Medical Sciences, New Delhi. Hospital antibiotic policy manual (current edition). Sections on first-generation cephalosporin use, IV-to-oral switch protocols, SSTI and UTI management.
FOGSI Guidelines — Federation of Obstetric and Gynaecological Societies of India. Guidelines on UTI in Pregnancy; Safe Drug Use in Pregnancy and Lactation.
ICRP (Indian Council of Rheumatic Prevention) — Guidelines on primary and secondary prevention of acute rheumatic fever and rheumatic heart disease.

International Textbooks (Pharmacology & Medicine):

Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (eds). Chapter on Cephalosporins (Chapter 58 / Beta-Lactam Antibiotics). Used for: detailed pharmacology, pharmacokinetics (bioavailability, Vd, protein binding, half-life, excretion, metabolism, transporter data), mechanism of action, spectrum of activity, PK/PD principles (fT>MIC), cross-reactivity between beta-lactams.
Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Loscalzo J, Fauci AS, Kasper DL, et al (eds). Chapters on: Infectious Disease (Cellulitis, Pharyngitis, UTI, Osteomyelitis); Antimicrobial Agents (Cephalosporins). Used for: clinical context of cefadroxil indications, treatment durations, disease management principles.

Key Clinical Trials / Studies:

Pichichero ME, Gooch WM, Rodriguez W, et al. “Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis: Ten days of penicillin V vs. 5 days or 10 days of cefadroxil.” Arch Pediatr Adolesc Med, 1994; 148(10):1053-1060. — Evidence basis for cefadroxil OD dosing for GAS pharyngitis.
Disney FA, Dillon H, Blumer JL, et al. “Cephalosporin treatment of pharyngitis and tonsillitis: a comparison of cefadroxil once daily vs. twice daily.” Clin Pediatr (Phila), 1992; 31(3):159-167. — Evidence basis for OD vs BD cefadroxil dosing equivalence for GAS pharyngitis.
OVIVA Trial — Li HK, Rombach I, Zamber R, et al. “Oral versus intravenous antibiotics for bone and joint infection.” N Engl J Med, 2019; 380(5):425-436. — Context for oral step-down in osteomyelitis (references cephalexin/flucloxacillin, not cefadroxil specifically — used to support the recommendation that cephalexin, not cefadroxil, is preferred for osteomyelitis step-down).
DANCE Trial — Cranendonk DR, Lavrijsen APM, Prins JM, et al. “Cellulitis treatment duration: a randomized clinical trial.” N Engl J Med, 2024. — Evidence for short-course cellulitis treatment (5 vs 12 days). Referenced for SSTI duration guidance.

Lactation Reference:

LactMed (Drugs and Lactation Database) — National Library of Medicine (NIH). Monograph on Cefadroxil. Accessed 2025. Used for: breast milk excretion data, relative infant dose (RID), compatibility assessment.

Renal Dosing Reference:

Aronoff GR, Bennett WM, Berns JS, et al.Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th Edition. American College of Physicians, 2007. Cefadroxil renal dosing table.

International Clinical Practice Guidelines (referenced where Indian guidelines are silent or for additional context):

IDSA Practice Guidelines for Acute Bacterial Rhinosinusitis, Pharyngitis, SSTI, and UTI — Various authors, published in Clinical Infectious Diseases, 2011–2014. Referenced for: treatment duration, empiric therapy guidance, treatment failure criteria.
AHA Guidelines for Prevention of Infective Endocarditis — Wilson W, Taubert KA, Gewitz M, et al. Circulation, 2007; 116(15):1736-1754. Updated 2021. Referenced for: IE prophylaxis dosing, indications for prophylaxis, drug selection.
AAP Clinical Practice Guideline: Diagnosis and Management of Acute Otitis Media — Lieberthal AS, Carroll AE, Chonmaitree T, et al. Pediatrics, 2013; 131(3):e964-e999. Referenced for: AOM management algorithm, antibiotic selection, observation option.
WHO Model Prescribing Information: Drugs Used in Bacterial Infections — World Health Organization. Referenced for: cefadroxil pregnancy safety, general dosing guidance.

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...